



# **R** **RESEARCH OPPORTUNITIES** **ALERT**

Issue 36: Volume 1b



## **GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)**

(Quarter: May – June, 2019)

*A Compilation by the*

PRE- & POST AWARD SERVICES  
OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID)  
UNIVERSITY OF GHANA

**APRIL 2019**

**Research Grants**

**Innovation Grants**

**Academic-Industry Grants**

**Collaborative Opportunities**

**Technology Development Grants**



## TABLE OF CONTENT

BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (U01 clinical trial not allowed) .....	26
BRAIN initiative – optimisation of transformative technologies for large scale recording and modulation in the nervous system (U01 clinical trials not allowed) .....	26
BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed) .....	26
BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (R01 clinical trial not allowed) .....	27
Refinement and testing of interventions to sustain ADHD treatment effects across settings and developmental transitions (R34 clinical trial required).....	27
Secondary data analysis to examine long-term or potential cross-over effects of prevention interventions – what are the benefits for preventing mental health disorders (R01 clinical trial not allowed) .....	27
Next generation multipurpose prevention technologies (R01 clinical trial optional) .....	28
HIV infection of the central nervous system (R01) .....	28
International research collaboration on drug abuse and addiction research (R01 clinical trial optional): AIDS-related.....	28
Dissemination and implementation research in health (R21 clinical trial optional): AIDS-related.....	29
Imaging – science track award for research transition (R03 clinical trial optional): AIDS-related.....	29
Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed): AIDS-related.....	29
Small research grant programme (parent R03 clinical trial not allowed): AIDS-related .....	30
Exploratory or developmental research grant programme (parent R21 clinical trial not allowed): AIDS-related .....	30
NEI research grant for vision related secondary data analysis (R21): Aids-related .....	30
Prescription drug abuse (R21 clinical trial optional): AIDS-related.....	31



Pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21): AIDS-related .....31

Exploratory/developmental bioengineering research grants (R21 clinical trial optional): AIDS-related.....31

Bioengineering research grants (R01 clinical trial optional): AIDS-related.....32

Mechanisms, models, measurement and management in pain research (R21 clinical trial optional): AIDS-related.....32

Mechanisms, models, measurement and management in pain research (R01 clinical trial optional): AIDS-related.....32

Research project grant (parent R01 clinical trial required): AIDS-related.....33

Chronic condition self-management in children and adolescents (R21 clinical trial optional): AIDS-related .....33

Prescription drug abuse (R01 clinical trial optional): AIDS-related.....33

Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R21): AIDS-related.....34

Neuroscience research on drug abuse (R01 clinical trial optional): AIDS-related .....34

Neuroscience research on drug abuse (R21 clinical trial optional): AIDS-related .....34

Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional): AIDS-related.....35

Women and sex or gender differences in drug and alcohol abuse or dependence (R03 clinical trial optional): AIDS-related.....35

Women and sex/gender differences in drug and alcohol abuse/dependence (R21 clinical trial optional): AIDS-related.....35

Development of animal models and related biological materials for research (R21): Aids-related.....36

AIDS-science track award for research transition (R03 clinical trial optional) ....36

Bioengineering research partnerships (U01 clinical trial required): AIDS-related .....36

Reducing health disparities among minority and underserved children (R21 clinical trial optional): AIDS-related.....37

Nutrition and alcohol-related health outcomes (R01): AIDS-related .....37

Nutrition and alcohol-related health outcomes (R03): AIDS-related .....37

Nutrition and alcohol-related health outcomes (R21): AIDS-related .....38



National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03): Aids-related .....	38
Health promotion among racial and ethnic minority males (R21 clinical trial optional): AIDS-related.....	38
Health promotion among racial and ethnic minority males (R01 clinical trial optional): AIDS-related.....	39
Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01): AIDS-related .....	39
Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R21): AIDS-related .....	39
Research on alcohol-related public policies such as those detailed in the alcohol policy information system (R03): AIDS-related .....	40
Epidemiology and prevention in alcohol research (R01 clinical trial optional): AIDS-related.....	40
Epidemiology and prevention in alcohol research (R21 clinical trial optional): AIDS-related.....	40
Epidemiology and prevention in alcohol research (R03 clinical trial optional): AIDS-related.....	41
Programme for extramural or intramural alcohol research collaborations (U01 clinical trial optional): AIDS-related.....	41
NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related .....	41
Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional): AIDS-related.....	42
Methodology and measurement in the behavioural and social sciences (R21 clinical trial optional): AIDS-related.....	42
Research to advance vaccine safety (R01 clinical trial not allowed): AIDS-related .....	42
.....	42
Research to advance vaccine safety (R21 clinical trial not allowed): AIDS-related .....	43
.....	43
Pilot and feasibility clinical research grants in urologic disorders (R21 clinical trial optional): AIDS-related .....	43
Secondary analyses in obesity, diabetes, digestive and kidney diseases (R21 clinical trial not allowed): AIDS-related.....	43
Pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34 clinical trial optional): AIDS-related.....	44
Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01): AIDS-related .....	44
Drug discovery for nervous system disorders (R21 clinical trial not allowed): AIDS-related.....	44



Drug discovery for nervous system disorders (R01 clinical trials not allowed): AIDS-related.....	45
Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional): AIDS-related .....	45
Obesity policy evaluation research (R01): AIDS-related.....	45
Small research grants for data analysis and statistical methodology applied to genome-wide data (R03): AIDS-related.....	46
NINDS efficacy clinical trials (U01 clinical trial required): AIDS-related .....	46
NINDS exploratory clinical trials (U01 clinical trial required): AIDS-related.....	46
.....	46
Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01): AIDS-related.....	47
Targeted basic behavioural and social science and intervention development for HIV prevention and care (R01 clinical trial optional) .....	47
Targeted basic behavioural and social science and intervention development for HIV prevention and care (R21 clinical trial optional) .....	47
Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional): AIDS-related.....	48
Healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21 clinical trial optional): AIDS-related.....	48
Alzheimer’s drug development programme (U01 clinical trial optional): AIDS- related .....	48
Discovery of in vivo chemical probes for novel brain targets (R01) AIDS-related .....	49
Pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34 clinical trial optional): AIDS-related .....	49
Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional): AIDS-related.....	49
.....	49
Environmental exposures and health: exploration of non-traditional settings (R21 clinical trial optional): AIDS-related.....	50
Mechanisms of alcohol-associated cancers (R01): AIDS-related .....	50
Mechanisms of alcohol-associated cancers (R21): AIDS-related .....	50
.....	50
NCI small grants programme for cancer research (NCI omnibus R03 clinical trial optional): AIDS-related.....	51
Development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34 clinical trial optional).....	51



Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional): AIDS-related.....51  
 .....51

Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional): AIDS-related.....52

Effects of in utero alcohol exposure on adult health and disease (R21 clinical trial optional): AIDS-related.....52

Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional): AIDS-related.....52

Selected topics in transfusion medicine (R21 clinical trial optional): AIDS-related .....53

Selected topics in transfusion medicine (R01 clinical trial optional): AIDS-related .....53

Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related.....53

Dissemination and implementation research in health (R03): Aids-related .....54

Research grants using the resources from the osteoarthritis initiative (R21): AIDS-related.....54

Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed): AIDS-related.....54

Biomarkers: bridging paediatric and adult therapeutics (R21): AIDS-related.....55

Development of appropriate paediatric formulations and paediatric drug delivery systems (R03): AIDS-related .....55

Development of appropriate paediatric formulations and paediatric drug delivery systems (R21): AIDS-related .....55

Development of appropriate paediatric formulations and paediatric drug delivery systems (R01): AIDS-related .....56

Chemical discovery award (R21/R33): Aids-related.....56

New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related.....56

Eradication of HIV-1 from central nervous system reservoirs (R01) .....57

Collaborative clinical vision project – resource center grant (UG1 clinical trial required): AIDS-related.....57

Clinical vision research: chair’s grant (UG1 clinical trial required): AIDS-related .....57  
 .....57



Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required): AIDS-related.....	58
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03 clinical trial optional): AIDS-related .....	58
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21 clinical trial optional): AIDS-related .....	58
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional): AIDS-related .....	59
Family-centred self-management of chronic conditions (R01 clinical trial optional): AIDS-related.....	59
Family-centred self-management of chronic conditions (R21 clinical trial optional): AIDS-related.....	59
Alcohol-induced effects on tissue injury and repair (R21): AIDS-related .....	60
Alcohol-induced effects on tissue injury and repair (R01): AIDS-related .....	60
Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional) .....	60
.....	60
Community partnerships to advance research (R21 clinical trial optional): AIDS-related .....	61
Community partnerships to advance research (R01 clinical trial optional): AIDS-related .....	61
mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R21 clinical trial optional): AIDS-related.....	61
mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional): AIDS-related.....	62
Natural killer cells to induce immunological memory to prevent HIV infection (R01).....	62
CREATE bio optimisation track for biologics (U01): AIDS-related .....	62
CREATE bio development track – nonclinical and early-phase clinical development for biologics (U01 clinical trial optional): AIDS-related.....	63
Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UH2/UH3 clinical trial optional): AIDS-related.....	63
Self-management for health in chronic conditions (R21 clinical trial optional): AIDS-related.....	63
Self-management for health in chronic conditions (R01 clinical trial optional): AIDS-related.....	64



Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R21 clinical trial optional): AIDS-related.....	64
Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R01 clinical trial optional): AIDS-related.....	64
Promoting research in basic neuroscience (R01 clinical trial not allowed): AIDS-related .....	65
Underactive bladder and detrusor activity in ageing (R03 clinical trial optional): AIDS-related.....	65
Underactive bladder and detrusor activity in ageing (R21 clinical trial optional): AIDS-related.....	65
Underactive bladder and detrusor activity in ageing (R01 clinical trial optional): AIDS-related.....	66
Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed): AIDS-related.....	66
Innovation grants to nurture initial translational efforts (IGNITE) – assay development and therapeutic agent identification (R61/R33 clinical trial not allowed): AIDS-related.....	66
Innovation grants to nurture initial translational efforts (IGNITE) – neurotherapeutic agent characterisation and in vivo efficacy studies (R61/R33 clinical trial not allowed): AIDS-related.....	67
Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional): AIDS-related .....	67
Prevention research in mid-life adults (R21 clinical trial optional): AIDS-related .....	67
Prevention research in mid-life adults (R01 clinical trial optional): AIDS-related .....	68
Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional): AIDS-related.....	68
Novel biomarkers for the development of HIV incidence assays with improved specificity (R21 clinical trial not allowed) .....	68
Early-life factors and cancer development later in life (R03 clinical trial not allowed): AIDS-related.....	69
Early-life factors and cancer development later in life (R21 clinical trial not allowed): AIDS-related.....	69
Early-life factors and cancer development later in life (R01 clinical trial not allowed): AIDS-related.....	69
Pilot and feasibility clinical research grants in kidney diseases (R21 clinical trial optional): AIDS-related.....	70
Diet and physical activity assessment methodology (R01 clinical trial not allowed): AIDS-related.....	70





Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional): AIDS-related .....	70
.....	70
Harnessing big data to halt HIV (R01 clinical trial optional).....	71
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related .....	71
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related .....	71
Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related.....	72
HIV/AIDS high priority drug abuse research (R01 clinical trial optional).....	72
Innovative questions in symptom science and genomics (R21 clinical trial optional): AIDS-related.....	72
Innovative questions in symptom science and genomics (R01 clinical trial optional): AIDS-related.....	73
Innovation grants to nurture initial translational efforts – development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R61/R33): AIDS-related.....	73
Applying metabolomics to drive biomarker discovery in symptom science (R21 clinical trial optional): AIDS-related.....	73
Applying metabolomics to drive biomarker discovery in symptom science (R01 clinical trial optional): AIDS-related.....	74
Natural history of disorders identifiable by screening of newborns (R01 clinical trial optional): AIDS-related .....	74
Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R21 clinical trial optional): AIDS-related .....	74
Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R01): AIDS-related .....	75
Multidisciplinary research in vulvodynia (R03): AIDS-related .....	75
Multidisciplinary research in vulvodynia (R21 clinical trial optional): AIDS-related .....	75
Multidisciplinary research in vulvodynia (R01 clinical trial optional): AIDS-related .....	76
Modelling of infectious disease agent study research projects (R01): Aids-related .....	76
Improvement of animal models for stem-cell-based regenerative medicine (R21): Aids-related.....	76
Improvement of animal models for stem-cell-based regenerative medicine (R01): Aids-related.....	77
Role of astrocytes and astrocytic networks in drug abuse (R21): Aids-related....	77



Population health interventions: integrating individual and group level evidence (R21 clinical trial not allowed): AIDS-related.....	77
Role of astrocytes and astrocytic networks in drug abuse (R01): Aids-related....	78
Population health interventions: integrating individual and group level evidence (R01 clinical trials not allowed): AIDS-related .....	78
Tailoring dental treatment for individuals with systemic diseases that compromise oral health (R21): Aids-related .....	78
Understanding factors in infancy and early childhood that influence obesity development (R01 clinical trial optional): AIDS-related.....	79
Exploratory grants in cancer epidemiology and genomics research (R21): AIDS-related .....	79
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R21 clinical trial optional): AIDS-related.....	79
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R03 clinical trial optional): AIDS-related.....	80
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional): AIDS-related.....	80
Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01): AIDS-related.....	80
Outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (R01 clinical trial optional): AIDS-related .....	81
Role of mobile genetic elements in cancer (R21): AIDS-related .....	81
Role of mobile genetic elements in cancer (R01): AIDS-related .....	81
Metabolic reprogramming to improve immunotherapy (R21): AIDS-related.....	82
Non-healing ulcerative wounds in ageing (R21): Aids-related.....	82
Metabolic reprogramming to improve immunotherapy (R01): Aids-related.....	82
Non-healing ulcerative wounds in ageing (R01): Aids-related.....	83
Mechanisms of cancer and treatment-related symptoms and toxicities (R21): Aids-related.....	83
Serious adverse drug reaction research (R21): Aids-related .....	83
Serious adverse drug reaction research (R01): Aids-related .....	84
Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional): AIDS-related.....	84
Integrative research on polysubstance abuse and addiction (R21/R33 clinical trial optional): AIDS-related .....	84
Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01): Aids-related.....	85
Safety and outcome measures of pain medications used in children and pregnant women (R03 clinical trial optional): AIDS-related .....	85



Safety and outcome measures of pain medications used in children and pregnant women (R21 clinical trial optional): AIDS-related .....	85
Safety and outcome measures of pain medications used in children and pregnant women (R01 clinical trial optional): AIDS-related .....	86
Assay development and screening to discover therapeutic or imaging agents for diseases of interest to the NIDDK (R01): Aids-related.....	86
Engineering next-generation human nervous system microphysiological systems (R21): Aids-related.....	86
Secondary analyses of alcohol and chronic disease (R03): AIDS-related .....	87
Engineering next-generation human nervous system microphysiological systems (R01): AIDS-related.....	87
Secondary analyses of alcohol and chronic disease (R01): Aids-related .....	87
High or medium priority AIDS research on non-AIDS-defining or AIDS-defining cancers (R21) .....	88
High or medium priority AIDS research on non-Aids-defining or Aids-defining cancers (R01) .....	88
Symptom management in HIV-infected individuals with comorbid conditions (R21 clinical trial optional): AIDS-related.....	88
Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional): AIDS-related.....	89
Basic and translational research on decision making in ageing and Alzheimer's disease (R01): AIDS-related .....	89
Trophoblast differentiation and function (R21 clinical trial optional): AIDS-related .....	89
Trophoblast differentiation and function (R01): AIDS-related .....	90
Palliative care needs of individuals with rare advanced diseases and their family caregivers (R21 clinical trial optional): AIDS-related .....	90
Improving individual and family outcomes through continuity and coordination of care in hospice (R21 clinical trial optional): AIDS-related .....	90
Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R21 clinical trial optional): AIDS-related .....	91
Self-management interventions and technologies to sustain health and optimise functional capabilities (R21 clinical trial optional): AIDS-related.....	91
Use of technology to enhance patient outcomes and prevent illness (R21 clinical trial optional): AIDS-related .....	91
Palliative care needs of individuals with rare advanced diseases and their family caregivers (R01 clinical trial optional): AIDS-related .....	92
Improving individual and family outcomes through continuity and coordination of care in hospice (R01 clinical trial optional): AIDS-related .....	92



Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R01 clinical trial optional): AIDS-related .....	92
Self-management interventions and technologies to sustain health and optimise functional capabilities (R01 clinical trial optional): AIDS-related.....	93
Use of technology to enhance patient outcomes and prevent illness (R01 clinical trial optional): AIDS-related .....	93
Promoting caregiver health using self-management (R01 clinical trial optional): AIDS-related.....	93
Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional): AIDS-related .....	94
Tobacco use and HIV in low- and middle-income countries (R21 clinical trial optional): AIDS-related.....	94
Tobacco use and HIV in low- and middle-income countries (R01 clinical trial optional): AIDS-related.....	94
Exploratory analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R21): AIDS-related .....	95
Strengthening the HIV pre-exposure prophylaxis care continuum through behavioural, social and implementation science (R21 clinical trial optional).....	95
Strengthening the HIV pre-exposure prophylaxis care continuum through behavioural, social, and implementation science (R01 clinical trial optional).....	95
Reducing health disparities among minority and underserved children (R01 clinical trial optional): AIDS-related.....	96
Chronic condition self-management in children and adolescents (R01 clinical trial optional): AIDS-related .....	96
Basic mechanisms of brain development mediating substance use and dependence (R01): AIDS-related.....	96
Zika virus complications (R21 clinical trial optional): AIDS-related.....	97
Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R21 clinical trial optional): AIDS-related .....	97
Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional): AIDS-related .....	97
Formative and pilot intervention research for prevention and treatment of HIV/AIDS (R34 clinical trial optional).....	98
Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R21 clinical trial optional) .....	98
Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21): AIDS-related .....	98
Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R01 clinical trial optional): AIDS-related .....	99



Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R21 clinical trial optional).....	99
Marijuana, prescription opioid, or prescription benzodiazepine drug use among older adults (R03): AIDS-related .....	99
Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R01 clinical trial optional): AIDS-related .....	100
Clinical studies of mental illness not involving clinical trials (collaborative R01): AIDS-related.....	100
Exploratory and developmental research grant (R21 clinical trial optional): AIDS-related.....	100
Promoting NICHD areas of research for HIV/AIDS in maternal and child health (R01) .....	101
Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R21): AIDS-related .....	101
HIV and hepatitis B co-infection – advancing HBV functional cure through clinical research (R01) .....	101
Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R01): AIDS-related .....	102
Small grants for secondary analyses of existing data sets and stored biospecimens (R03) AIDS-related.....	102
Imaging the persistent HIV reservoir (R01) .....	102
Optimising HIV phylodynamics to target and interrogate clusters (R21).....	103
Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional): AIDS-related.....	103
Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional): AIDS-related.....	103
Ethical, legal and social implications of genomics research small research grant programme (R03): AIDS-related .....	104
Ethical, legal and social implications of genomics research exploratory/developmental research programme (R21): AIDS-related .....	104
Ethical, legal and social implications of genomic research regular research programme (R01): AIDS-related .....	104
Using small molecules and molecular genetics to identify novel targets and mechanisms contributing to tumour immune evasion (R01): AIDS-related.....	105
Discovery of cell-based chemical probes for novel brain targets (R21): AIDS-related .....	105
Synthetic biology for engineering (R01 clinical trial optional): AIDS-related ....	105
Assay development and screening for discovery of chemical probes or therapeutic agents (R01): AIDS-related.....	106



NIBIB exploratory/developmental research grant programme (R21 clinical trial optional): AIDS-related.....	106
Secondary analyses of existing alcohol research data (R03) AIDS-related.....	106
Secondary analyses of existing alcohol research data (R01): AIDS-related .....	107
Understanding and modifying temporal dynamics of coordinated neural activity (R21 clinical trial optional): AIDS-related.....	107
Understanding and modifying temporal dynamics of coordinated neural activity (R01 clinical trial optional): AIDS-related.....	107
Research on the health of transgender and gender nonconforming populations (R21 clinical trial optional): AIDS-related.....	108
Research on the health of transgender and gender nonconforming populations (R01 clinical trial optional): AIDS-related.....	108
New onset depressive symptoms in acute illness (R21 clinical trial not allowed): AIDS-related.....	108
New onset depressive symptoms in acute illness (R01 clinical trial not allowed): AIDS-related.....	109
Addressing chronic wound trajectories through social genomics research (R21: clinical trial optional): AIDS-related.....	109
Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R21 clinical trial optional): AIDS-related .....	109
Addressing chronic wound trajectories through social genomics research (R01 clinical trial optional): AIDS-related.....	110
Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R01 clinical trial optional): AIDS-related .....	110
Fundamental science research on mind and body approaches (R21 clinical trial optional): AIDS-related.....	110
Fundamental science research on mind and body approaches (R01 clinical trial optional): AIDS-related.....	111
Investigator-initiated clinical trials targeting diseases within the mission of NIDDK (R01 clinical trial required): AIDS-related.....	111
The application of big data analytics to drug abuse research (R01 clinical trial optional): AIDS related .....	111
Advancing understanding, prevention, and management of infections transmitted from women to their infants (R21 clinical trial optional): AIDS-related .....	112
Advancing understanding, prevention, and management of infections transmitted from women to their infants (R01 clinical trial optional): AIDS-related .....	112
.....	112
Exploratory or developmental research grant programme (parent R21 clinical trial required): AIDS-related .....	112



NIMH exploratory/developmental research grant (R21 clinical trial not allowed): AIDS-related.....	113
Human subjects mechanistic and minimal risk studies (R01 clinical trial optional): AIDS-related.....	113
NIDCD clinical trials in communication disorders (R01 clinical trial required): AIDS-related.....	113
NINDS exploratory neuroscience research grant (R21 clinical trial optional): AIDS-related.....	113
Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional): AIDS-related.....	114
Population health interventions – integrating individual and group level evidence (R01 clinical trial optional): AIDS-related .....	114
Population health interventions – integrating individual and group level evidence (R21 clinical trial optional): AIDS-related .....	114
Feasibility clinical trials of mind and body interventions for NCCIH high priority research topics (R34 clinical trial required): AIDS-related.....	115
NIBIB research project grant (R01 clinical trial required): AIDS-related .....	115
Obesity and asthma – awareness and self-management (R01 clinical trial optional): AIDS-related.....	115
NICHD small grant programme (R03 clinical trial optional): AIDS-related.....	116
NICHD research project grant (R01 clinical trial required): AIDS-related.....	116
Research project grant (parent R01 clinical trial not allowed): AIDS-related....	116
End-of-life and palliative care health literacy – improving outcomes in serious, advanced illness (R01 clinical trial optional): AIDS-related .....	117
Human subjects mechanistic and minimal risk studies (R21 clinical trial optional): AIDS-related.....	117
End-of-life and palliative care health literacy: improving outcomes in serious, advanced illness (R21 clinical trial optional): AIDS-related .....	117
Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial optional): AIDS-related.....	118
Analytical validation of candidate biomarkers for neurological disease (U01 clinical trial optional): AIDS-related.....	118
Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional): AIDS-related .....	118
Cancer prevention and control clinical trials grant programme (R01 clinical trial required): AIDS-related.....	119
Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required): AIDS-related .....	119
Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial optional): AIDS-related.....	119



Understanding processes of recovery in the treatment of alcohol use disorder (R01 clinical trial optional): AIDS-related.....	120
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01 clinical trial optional): AIDS-related.....	120
Disease mechanisms of prenatal and paediatric hydrocephalus (R01 clinical trial not allowed): AIDS-related.....	120
NIDA small research grant programme (R03 clinical trial required): AIDS-related .....	121
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21 clinical trial optional): AIDS-related.....	121
Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed): AIDS-related.....	121
Developmentally tailored HIV prevention and care research for adolescents and young adults (R01 clinical trial optional).....	121
Developmentally tailored HIV prevention and care research for adolescents and young adults (R21 clinical trial not allowed).....	122
Developmentally tailored HIV prevention and care research for adolescents and young adults (R34 clinical trial optional).....	122
Genetics of alcohol sensitivity and tolerance (R01 clinical trial not allowed): AIDS-related.....	122
Clinical validation of a candidate biomarker for neurological disease (U01 clinical trial optional): AIDS-related .....	123
Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed): AIDS-related .....	123
Developmental pharmacodynamics and models of drug effects in paediatrics (R01 clinical trial optional): AIDS-related.....	123
Innovative therapies and tools for screenable disorders in newborns (R01 clinical trial optional): AIDS-related.....	123
Developmental pharmacodynamics and models of drug effects in paediatrics (R03 clinical trial optional): AIDS-related.....	124
Innovative therapies and tools for screenable disorders in newborns (R03 clinical trial optional): AIDS-related.....	124
Innovative therapies and tools for screenable disorders in newborns (R21 clinical trial optional): AIDS-related.....	124
High priority HIV/AIDS research within the mission of the NIDDK (R01 clinical trial optional): AIDS-related .....	125
Basic and translational oral health research related to HIV/AIDS (R01 clinical trial not allowed): AIDS-related .....	125
Basic and translational oral health research related to HIV/AIDS (R21 clinical trial not allowed): AIDS-related .....	125





Improving patient adherence to treatment and prevention regimens to promote health (R01 clinical trial optional): AIDS-related.....	126
Improving patient adherence to treatment and prevention regimens to promote health (R21 clinical trial optional) – AIDS-related.....	126
Small research grants for establishing basic science-clinical collaborations to understand structural birth defects (R03 clinical trial not allowed): AIDS-related .....	126
Small research grants for analyses of data for the Gabriella Miller Kids First Data Resource (R03 clinical trial not allowed): AIDS-related.....	127
Precision imaging of oral lesions (R01 clinical trial not allowed): AIDS-related .....	127
Precision imaging of oral lesions (R21 clinical trial not allowed): AIDS-related .....	127
Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21 clinical trial optional): AIDS-related .....	128
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional): AIDS-related .....	128
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional): AIDS-related .....	128
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional): AIDS-related.....	129
Vision research epidemiology grant (UG1 clinical trial not allowed): AIDS-related .....	129
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional): AIDS-related.....	129
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R21 clinical trial optional): AIDS-related.....	130
Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional): AIDS-related.....	130
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed): AIDS-related.....	130
Applying a biopsychosocial perspective to self-management of chronic pain (R01 clinical trial optional): AIDS-related.....	131
Biobehavioural basis of chronic pain (R01 clinical trial optional): AIDS-related .....	131
Applying a biopsychosocial perspective to self-management of chronic pain (R21 clinical trial optional): AIDS-related.....	131
Biobehavioural basis of chronic pain (R21 clinical trial optional): AIDS-related .....	132



Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed): AIDS-related.....	132
Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related.....	132
Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related.....	133
Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related.....	133
End-of-life and palliative care approaches to advanced signs and symptoms (R01 clinical trial optional): AIDS-related.....	133
Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related.....	134
End-of-life and palliative care approaches to advanced signs and symptoms (R21 clinical trial optional): AIDS-related.....	134
Engaging men in HIV testing, prevention and care (R01 clinical trial optional)	134
.....	134
Engaging men in HIV testing, prevention and care (R21 clinical trial optional)	135
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related.....	135
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional): AIDS-related.....	135
Clinical trial planning grant (R34 clinical trial required): AIDS-related .....	136
Processing and presentation of non-conventional MHC ligands (R01 clinical trial not allowed): AIDS-related.....	136
Processing and presentation of non-conventional MHC ligands (R21 clinical trial not allowed): AIDS-related.....	136
Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional): AIDS-related .....	137
Telomeres in wellness and disease – a biobehavioural approach (R21 clinical trial optional): AIDS-related .....	137
Research project grant (parent R01 basic experimental studies with humans required): AIDS-related.....	137
Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related .....	138
Research to advance hepatitis B virus cure – HIV/HBV co-infection and HBV mono-infection (R01 clinical trial not allowed): AIDS-related .....	138
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trial not allowed): AIDS-related.....	138



Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trial not allowed): AIDS-related.....	139
Bioengineering research grants (R01 clinical trial not allowed): AIDS-related.	139
Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related .....	139
Exploratory/developmental bioengineering research grants (R21 clinical trial not allowed): AIDS-related.....	140
Progression markers for cognitive impairment in Parkinson's disease dementia (R01 clinical trial not allowed): AIDS-related.....	140
Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinical trial not allowed): AIDS-related .....	140
Secondary analyses of existing datasets in heart, lung and blood diseases and sleep disorders (R21): AIDS-related .....	141
Quantitative imaging tools and methods for cancer therapy response assessment (UG3/UH3 clinical trial optional) .....	141
NIAID clinical trial planning grant (R34) .....	141
NIAID clinical trial implementation cooperative agreement (U01 clinical trial required) .....	142
NIAID clinical trial implementation grant (R01).....	142
Single-site investigator-initiated clinical trials (R61/R33: clinical trial required): AIDS-related.....	142
Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related .....	143
Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required): AIDS-related.....	143
Administrative supplement for research on bioethical issues (admin supp clinical trial optional).....	143
Administrative supplements for geospatial, multilevel and contextual approaches in cancer control and population sciences.....	144
Administrative supplements to promote data sharing in cancer epidemiology studies .....	144
Functional RNA modifications environment and disease (R01 clinical trial not allowed).....	144
Functional RNA modifications environment and disease (R21 clinical trial not allowed).....	145
BLOODSAFE – research to enhance availability of safe blood for patients with severe anaemia and haemorrhagic conditions in low or lower-middle income countries in sub-Saharan Africa (UG3/UH3 clinical trial optional) .....	145
International research in infectious diseases including AIDS (R01) .....	145



Innovative research in cancer nanotechnology (R01) .....	146
Collaborative clinical vision project – resource center grant (UG1 clinical trial required) .....	146
Clinical vision research: chair’s grant (UG1 clinical trial required).....	146
Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required) .....	146
Genomic community resources (U24).....	147
Vision research epidemiology grant (UG1 clinical trial not allowed) .....	147
Advanced development and validation of emerging biospecimen science technologies for basic and clinical cancer research (R33 clinical trial not allowed) .....	147
Innovative biospecimen science technologies for basic and clinical cancer research (R21 clinical trial not allowed) .....	147
Advanced development and validation of emerging molecular and cellular analysis technologies for basic and clinical cancer research (R33 clinical trial not allowed) .....	148
Innovative molecular and cellular analysis technologies for basic and clinical cancer research (R21).....	148
Revisions for incorporation of novel NCI-supported technology to accelerate cancer research (R01 clinical trial optional).....	148
Revisions for incorporation of novel NCI-supported technology to accelerate cancer research (U01 clinical trial optional).....	149
Perception and cognition research to inform cancer image interpretation (R21 clinical trial optional) .....	149
Perception and cognition research to inform cancer image perception (R01 clinical trial optional) .....	149
.....	149
NCCIH mind and body clinical trial cooperative agreement (U01).....	150
Serious adverse drug reaction research (R21) .....	150
Serious adverse drug reaction research (R01) .....	150
Role of epitranscriptomics in development and disease (R01 clinical trial not allowed).....	150
Role of epitranscriptomics in development and disease (R21 clinical trial not allowed).....	151
BRAIN initiative – biology and biophysics of neural stimulation (R01 clinical trial optional) .....	151
Optimisation of non-addictive small molecules and biologics therapies to treat pain (UG3/UH3 clinical trial not allowed) .....	151
Diet and physical activity assessment methodology (R01 clinical trial not allowed).....	152



International research collaboration on drug abuse and addiction research (R01 clinical trial optional) .....	152
Bioengineering research grants (R01 clinical trial required) .....	152
Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional) .....	152
Bioengineering research partnerships (U01 clinical trial required) .....	153
Ethical, legal and social implications of genomic research regular research programme (R01) .....	153
Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed) .....	153
Research project grant (parent R01 clinical trial required) .....	153
Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01) .....	154
Neuroscience research on drug abuse (R01 clinical trial optional) .....	154
Nutrition and alcohol-related health outcomes (R01) .....	154
Health promotion among racial and ethnic minority males (R01 clinical trial optional) .....	155
Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01) .....	155
Epidemiology and prevention in alcohol research (R01 clinical trial optional) .....	155
Genetic susceptibility and variability of human structural birth defects (R01) .....	155
NLM research grants in biomedical informatics and data science (R01 clinical trial optional) .....	156
Investigations on primary immunodeficiency diseases/inborn errors of immunity (R01 clinical trial not allowed) .....	156
Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional) .....	156
Research to advance vaccine safety (R01 clinical trial not allowed) .....	157
Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01) .....	157
Drug discovery for nervous system disorders (R01 clinical trials not allowed) .....	157
Alzheimer's drug development programme (U01 clinical trial optional) .....	158
Research on autism spectrum disorders (R01 clinical trial optional) .....	158
Mechanisms of alcohol-associated cancers (R01) .....	158
NINDS exploratory clinical trials (U01 clinical trial required) .....	158
NINDS efficacy clinical trials (U01 clinical trial required) .....	159
Novel biomarkers for the development of HIV incidence assays with improved specificity (R01 clinical trial optional) .....	159



Hearing health care for adults – improving access and affordability (R01 clinical trial optional).....	159
Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01)....	160
Obesity and asthma – awareness and self-management (R01 clinical trial optional) .....	160
Cellular and molecular biology of complex brain disorders (R01) .....	160
Development of appropriate paediatric formulations and paediatric drug delivery systems (R01).....	161
Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed).....	161
Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional) .....	161
Health tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional) .....	162
NeuroNEXT clinical trials (U01 clinical trial optional) .....	162
Mechanisms mediating osteoarthritis in ageing (R01).....	162
Discovery of in vivo chemical probes for novel brain targets (R01) .....	163
Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional) .....	163
Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional).....	163
Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional) .....	164
Juvenile protective factors and their effects on ageing (R01) .....	164
Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional) ...	164
Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional) .....	165
Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional).....	165
Biomarkers for diabetes, digestive, kidney and urologic diseases using biosamples from the NIDDK repository (R01).....	165
.....	165
Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed).....	166
Advancing the science of geriatric palliative care (R01 clinical trial optional) ..	166
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed).....	166



New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed) .....	167
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional).....	167
Family-centred self-management of chronic conditions (R01 clinical trial optional) .....	167
Alcohol-induced effects on tissue injury and repair (R01) .....	167
Community partnerships to advance research (R01 clinical trial optional) .....	168
Clinical studies of mental illness not involving clinical trials (collaborative R01) .....	168
StrokeNet clinical trials and biomarker studies for stroke treatment, recovery and prevention (U01 clinical trial optional).....	168
Collaborative research projects to enhance applicability of mammalian models for translational research (collaborative R01).....	169
Research projects to enhance applicability of mammalian models for translational research (R01) .....	169
Research on chronic overlapping pain conditions (R01).....	169
Self-management for health in chronic conditions (R01 clinical trial optional)	169
Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R01 clinical trial optional) .....	170
Promoting research in basic neuroscience (R01 clinical trial not allowed) .....	170
Underactive bladder and detrusor activity in ageing (R01 clinical trial optional) .....	170
Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional).....	171
Prevention research in mid-life adults (R01 clinical trial optional) .....	171
Early-life factors and cancer development later in life (R01 clinical trial not allowed).....	171
Achieving tissue robustness through harnessing immune system plasticity (R01 clinical trial not allowed) .....	172
Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional).....	172
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional).....	172
Late stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial required).....	172
Early-stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial optional).....	173



Advancing understanding, prevention, and management of infections transmitted from women to their infants (R01 clinical trial optional) .....	173
Improving outcomes in cancer treatment-related cardiotoxicity (R01 clinical trial optional) .....	173
Diet and physical activity assessment methodology (R01).....	174
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional) .....	174
Role of mobile genetic elements in cancer (R01).....	174
Metabolic reprogramming to improve immunotherapy (R01).....	174
Non-healing ulcerative wounds in ageing (R01) .....	175
.....	175
Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R01).....	175
Gene fusion in paediatric sarcomas (R01).....	175
Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional) .....	176
Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01) .....	176
Characterisation of the adolescent reproductive transition (R01 clinical trial optional) .....	176
Safety and outcome measures of pain medications used in children and pregnant women (R01 clinical trial optional).....	177
Metabolic contributions to the neurocognitive complications of diabetes: ancillary studies (R01 clinical trial optional).....	177
Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for aging-related conditions (R01).....	177
Assay development and screening to discover therapeutic or imaging agents for diseases of interest to the NIDDK (R01).....	178
Engineering next-generation human nervous system microphysiological systems (R01).....	178
Secondary analyses of alcohol and chronic disease (R01) .....	178
Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional).....	179
Trophoblast differentiation and function (R01).....	179
Palliative care needs of individuals with rare advanced diseases and their family caregivers (R01 clinical trial optional).....	179
Improving individual and family outcomes through continuity and coordination of care in hospice (R01 clinical trial optional) .....	180





Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R01 clinical trial optional) .....	180
Self-management interventions and technologies to sustain health and optimise functional capabilities (R01 clinical trial optional) .....	180
Use of technology to enhance patient outcomes and prevent illness (R01 clinical trial optional).....	181
Improving quality of care and quality of life for persons with Alzheimer’s disease and related dementias at the end of life (R01: clinical trial optional) .....	181
Dynamic interactions between systemic or non-neuronal systems and the brain in ageing and in Alzheimer’s disease (R01).....	181
Integrative research to understand the impact of sex differences on the molecular determinants of Alzheimer’s disease risk and responsiveness to treatment (R01) .....	182
Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer’s disease (R01) .....	182
Role of age-associated metabolic changes in Alzheimer’s disease (R01) .....	182
Clarifying the relationship between delirium and Alzheimer’s disease and related dementias (R01 clinical trial optional).....	183
Selective cell and network vulnerability in ageing and Alzheimer’s disease (R01 clinical trial not allowed) .....	183
Leveraging existing cohort studies to clarify risk and protective factors for Alzheimer’s disease and related dementias (R01) .....	183
Promoting caregiver health using self-management (R01 clinical trial optional) .....	184
.....	184
Oral anticancer agents – utilisation, adherence and health care delivery (R01 clinical trial optional) .....	184
Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional).....	184
Fertility status as a marker for overall health (R01) .....	185
Academic-industrial partnerships to translate and validate in vivo cancer imaging systems (R01 clinical trial optional) .....	185
Chronic condition self-management in children and adolescents (R01 clinical trial optional).....	185
Reducing health disparities among minority and underserved children (R01 clinical trial optional) .....	186
Reducing overscreening for breast, cervical and colorectal cancers among older adults (R01 clinical trial optional) .....	186
Basic mechanisms of brain development mediating substance use and dependence (R01) .....	186



Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional) ..... 187

Advancing our understanding of the brain epitranscriptomics (R01) ..... 187

Cancer tissue engineering collaborative – enabling biomimetic tissue-engineered technologies for cancer research (R01 clinical trial optional) ..... 187



# MAY

## BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (U01 clinical trial not allowed)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity to enable transformative understanding of dynamic signalling

in the nervous system. A total of USD 10 million per year is shared between 15 to 20 awards.

**Closing date: 01 May 19**

[Link to \\*Research Professional](#)

## BRAIN initiative – optimisation of transformative technologies for large scale recording and modulation in the nervous system (U01 clinical trials not allowed)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports the optimisation of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity in any

region and throughout the entire depth of the brain. Funding is for three years.

**Closing date: 01 May 19**

[Link to \\*Research Professional](#)

## BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed)

### **NIH: National Eye Institute**

This seeks applications for unique and innovative technologies that are in early stages of development, including new and untested ideas that are in the initial stages of conceptualisation. The combined

budget for direct costs is USD 300,000 for up to two years.

**Closing date: 01 May 19**

[Link to \\*Research Professional](#)



## **BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (R01 clinical trial not allowed)**

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity to enable transformative understanding of dynamic signalling

in the nervous system. The total budget is USD 10 million per year to fund 15 to 20 awards.

**Closing date: 01 May 19**

[Link to \\*Research Professional](#)



## **Refinement and testing of interventions to sustain ADHD treatment effects across settings and developmental transitions (R34 clinical trial required)**

### **NIH: National Institute of Mental Health**

This supports pilot projects to evaluate the preliminary effectiveness of augmented or modified interventions designed to promote sustained improvement in attention-deficit/hyperactivity disorder symptoms and functional

impairments. Grants are worth up to USD 450,000 each for a maximum period of three years.

**Closing date: 01 May 19**

[Link to \\*Research Professional](#)



## **Secondary data analysis to examine long-term or potential cross-over effects of prevention interventions – what are the benefits for preventing mental health disorders (R01 clinical trial not allowed)**

### **NIH: National Institute of Mental Health**

This supports research to integrate existing data sets from preventive intervention trials implemented early in life. Application budgets are limited to USD 500,000 direct costs

in any project year. The maximum project period is three years.

**Closing date: 02 May 19**

[Link to \\*Research Professional](#)





## Next generation multipurpose prevention technologies (R01 clinical trial optional)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of new and innovative on-demand, event-driven and long-acting systemic and non-systemic multipurpose prevention

technologies. The maximum project period is five years.

**Closing date: 06 May 19**

[Link to \\*Research Professional](#)



## HIV infection of the central nervous system (R01)

### **NIH: National Institute of Mental Health**

This announcement supports research projects that focus on defining and understanding the pathogenic mechanisms involved in human immunodeficiency virus-1 induced CNS dysfunction, but within the context of viral suppression and antiretroviral therapy. Application

budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## International research collaboration on drug abuse and addiction research (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US with a focus on AIDS. Application budgets are not limited but must

reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Dissemination and implementation research in health (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This aids-related R21 funding opportunity announcement encourages investigators to submit research grant applications that will develop strategies to implement evidence-based practices into public health, clinical practice, and

community settings. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Imaging – science track award for research transition (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to

conduct small proof of concept studies. Awards are worth up to USD 150,000 for a maximum period of one year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related call aims to improve understanding of the causes of high priority diseases in the US and mitigate health disparities. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professiona](#)



### Small research grant programme (parent R03 clinical trial not allowed): AIDS-related

#### **NIH: National Human Genome Research Institute**

This AIDS-related funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are limited to USD 50,000 in direct costs

per year for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Exploratory or developmental research grant programme (parent R21 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related funding opportunity supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are limited to USD 275,000 for a two-

year period, with no more than USD 200,000 in any year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### NEI research grant for vision related secondary data analysis (R21): Aids-related

#### **NIH: National Eye Institute**

This Aids-related announcement encourages applications that propose to conduct vision-related secondary data analyses utilising existing database resources. Application budgets are limited to US\$275,000 for a maximum period

of two years. No more than US\$200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Prescription drug abuse (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse. Application

budgets are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related call supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases. Application

budgets are limited to USD 275,000 in direct costs over up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Exploratory/developmental bioengineering research grants (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or

clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Bioengineering research grants (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

These AIDS-related grants support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Mechanisms, models, measurement and management in pain research (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related announcement aims to stimulate and foster a wide range of basic, clinical and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are limited to USD 275,000

in direct costs for a maximum period of two years. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Mechanisms, models, measurement and management in pain research (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement aims to stimulate and foster a wide range of basic, clinical and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Research project grant (parent R01 clinical trial required): AIDS-related

### **NIH: National Heart, Lung and Blood Institute**

This supports a discrete, specified, circumscribed AIDS-related project in areas representing the specific interests and competencies of the investigators. Application budgets need to reflect the actual needs of

the proposed project. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Chronic condition self-management in children and adolescents (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages exploratory or developmental research that aims to improve self-management and quality of life in children and adolescents with chronic conditions. Application budgets are limited to

USD 275,000 in direct costs over two years, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Prescription drug abuse (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse. Application budgets are not limited, but must

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R21): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related announcement encourages basic functional genomic research that identifies genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use

disorders. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Neuroscience research on drug abuse (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports research to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence,

withdrawal and relapse to chronic substance abuse. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Neuroscience research on drug abuse (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports research on the neurobiological mechanisms underlying substance use disorders, with emphasis on identifying changes and neuroadaptations that occur during dependence,

withdrawal and relapse to chronic substance use. Grants are worth up to USD 275,000 for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity aims to advance identification of male-female differences in drug and alcohol research outcomes and to advance research specific to women or highly

relevant to women. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Women and sex or gender differences in drug and alcohol abuse or dependence (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity aims to advance identification of male-female differences in drug and alcohol research outcomes and to advance research specific to women or highly

relevant to women. Grants are worth up to USD 50,000 each per year over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Women and sex/gender differences in drug and alcohol abuse/dependence (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity aims to advance identification of male-females differences in drug and alcohol research outcomes, to uncover the mechanisms and to conduct translational research on these differences, and to advance research

specific to women. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Development of animal models and related biological materials for research (R21): Aids-related

### **NIH: Office of the Director**

This Aids-related announcement solicits proposals to develop, characterise or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes.

Application budgets are limited to US\$275,000 in direct costs over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## AIDS-science track award for research transition (R03 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This seeks to facilitate the entry of both newly independent and early-career investigators to the area of drug abuse research on HIV/AIDS. Awards are each worth up to USD

100,000 per year for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Bioengineering research partnerships (U01 clinical trial required): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related funding opportunity encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address

important biomedical problems. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Profession](#)



## Reducing health disparities among minority and underserved children (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages research that targets the reduction of health disparities among children. Application budgets are limited to USD 275,000 over a two-year period.

No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Nutrition and alcohol-related health outcomes (R01): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity announcement supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Nutrition and alcohol-related health outcomes (R03): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This Aids-related announcement supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. Grants are worth

up to USD 50,000 per year over a maximum of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Nutrition and alcohol-related health outcomes (R21): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity announcement supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. The combined budget for direct costs for the two-year project

period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03): Aids-related

### **NIH: National Institute of Dental and Craniofacial Research**

This Aids-related R03 funding opportunity announcement supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research.

Budgets for direct costs of up to USD 200,000 over a two-year period may be requested.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Health promotion among racial and ethnic minority males (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement aims to stimulate and expand research in the health of minority men. Application budgets are limited to USD 275,000 for the two-year project period, with no more than

USD 200,000 available in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Health promotion among racial and ethnic minority males (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement aims to stimulate and expand research in the health of minority men. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

The aim of this AIDS-related programme is to encourage research on the effects of public policies of health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Application budgets are not limited

but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R21): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

The AIDS-related funding opportunity announcement encourages research on the effects of public policies on health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Direct costs

are limited to USD 275,000 over an R21 two-year period, with no more than USD 200,000 allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Research on alcohol-related public policies such as those detailed in the alcohol policy information system (R03): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity announcement encourages applications to conduct research on the effects of public policies on health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Direct costs of up to USD

50,000 per year will be funded, with a total project period of a maximum of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Epidemiology and prevention in alcohol research (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related call supports research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms and alcohol use disorders. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Epidemiology and prevention in alcohol research (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related call supports research investigating the epidemiology of alcohol use, alcohol-related harms and alcohol use disorders, and the prevention of underage drinking, alcohol-related harms and alcohol use disorders.

Direct costs are limited to USD 275,000 over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Epidemiology and prevention in alcohol research (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related call supports research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. Application budgets are limited to

USD 50,000 in direct costs per year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Programme for extramural or intramural alcohol research collaborations (U01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity encourages collaboration between alcohol researchers in the extramural community and those within the NIAAA intramural research programme. Grants are worth up to

USD 250,000 per year for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related

### **NIH: National Library of Medicine**

This AIDS-related opportunity supports innovative research and development in biomedical informatics and data science. Grants are worth up to USD 250,000 each

per year over a maximum period of four years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional): AIDS-related

### **NIH: Office of the Director**

This AIDS-related funding opportunity supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Methodology and measurement in the behavioural and social sciences (R21 clinical trial optional): AIDS-related

### **NIH: Office of the Director**

This AIDS-related announcement supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. Application budgets are limited to USD 275,000 in direct

costs, with no more than USD 200,000 allowed in any single year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research to advance vaccine safety (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related opportunity supports research that will contribute to the overall understanding of vaccine safety. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Research to advance vaccine safety (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports research that will contribute to the overall understanding of vaccine safety. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Pilot and feasibility clinical research grants in urologic disorders (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This supports AIDS-related projects that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders

research. Grants are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Secondary analyses in obesity, diabetes, digestive and kidney diseases (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related call supports projects that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases, genetic metabolic disease, obesity, liver diseases, alimentary gastrointestinal tract diseases,

kidney, urological, and haematological diseases. Application budgets are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports research that provides intervention pilot or feasibility data serving as a prerequisite for subsequent applications for larger scale drug or alcohol abuse prevention or drug- or alcohol-

related HIV prevention intervention studies. Grants are worth up to USD 450,000 each over three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related call supports applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on ageing changes influencing health across the lifespan, and on diseases and disabilities in older persons.

Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Drug discovery for nervous system disorders (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related call supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Grants

are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Drug discovery for nervous system disorders (R01 clinical trials not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity supports the discovery of novel compounds for the prevention and treatment of nervous

system disorders. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related call supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the etiology and epidemiology of drug-using behaviours and related disorders, prevention of drug use

and HIV, and health service use. Direct costs are limited to USD 500,000 per year over a maximum period of five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Obesity policy evaluation research (R01): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related announcement encourages evaluations of large scale policies or programmes that are expected to influence obesity-related behaviours or weight outcomes in an effort to prevent or reduce obesity. Applications budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Small research grants for data analysis and statistical methodology applied to genome-wide data (R03): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This supports AIDS-related research that involves statistical analysis of existing genome-wide data relevant to human dental, oral, or craniofacial conditions or traits. Grants are

worth up to USD 200,000 each for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NINDS efficacy clinical trials (U01 clinical trial required): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke. Application budgets are not limited, but need to

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NINDS exploratory clinical trials (U01 clinical trial required): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related announcement supports investigator-initiated exploratory clinical trials within the mission and research interests of the National Institute of Neurological Disorders and Stroke. Application budgets are not limited but must

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related announcement encourages basic functional genomic research that identifies genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use

disorders. Applications budgets are not limited, but must reflect the needs of the project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Targeted basic behavioural and social science and intervention development for HIV prevention and care (R01 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages innovative, targeted basic behavioural and social science and intervention development research to reduce incident HIV infections and improve the health of those living with HIV. Application budgets are not limited but need to

reflect the actual needs of the project. The total project period may not exceed five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Targeted basic behavioural and social science and intervention development for HIV prevention and care (R21 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages innovative, targeted basic behavioural and social science and intervention development research to reduce incident HIV infections and improve the health of those living with HIV. Direct costs are limited to USD 275,000 over a

two-year project period, with no more than USD 200,000 allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity aims to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 18.

Application budgets are not limited, but need to reflect actual needs of

the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call encourages research to identify mechanisms of promoting positive sustainable health behaviour in children and youth up to the age of 18. The combined budget may not exceed

USD 275,000 for the two-year project period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Alzheimer's drug development programme (U01 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related opportunity supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease, slow its progression or treat its cognitive and behavioural

symptoms. Funding is worth up to USD 1 million per project per year for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Discovery of in vivo chemical probes for novel brain targets (R01) AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity supports investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials with a focus on AIDS. Grants

are worth up to USD 450,000 over three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings such as

playgrounds and nursing homes. Application budgets are not limited, but must reflect the actual needs of the project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Environmental exposures and health: exploration of non-traditional settings (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities in non-traditional settings where exposure to environmental pollutants and toxins may occur. Application budgets are

limited to USD 275,000 in direct costs over a two-year project period, with no more than USD 200,000 in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Mechanisms of alcohol-associated cancers (R01): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity announcement supports research that investigates cellular and molecular mechanisms by which alcohol increases cancer risk. Application budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Mechanisms of alcohol-associated cancers (R21): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity announcement supports research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. The combined budget for direct costs for the two year project period may not

exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## NCI small grants programme for cancer research (NCI omnibus R03 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports small research projects on cancer that can be carried out in a short period of time with limited resources. A budget for direct costs of up to USD 50,000 per year may be requested.

The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports formative research, intervention development and pilot-testing of HIV interventions among populations where substance use may be a contributing factor. Grants

are worth up to USD 450,000 each over three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This encourages transdisciplinary and translational AIDS-related research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect

cancer prognosis and survival. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related opportunity supports transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis

and survival. Grants are worth up to USD 275,000 each for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Effects of in utero alcohol exposure on adult health and disease (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related announcement supports novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Application

budgets are limited to USD 275,000 over a two-year project period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related announcement supports novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Application budgets are not limited, but must

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Selected topics in transfusion medicine (R21 clinical trial optional): AIDS-related

### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call supports research on topics related to blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine.

Application budgets are worth up to USD 275,000 for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Selected topics in transfusion medicine (R01 clinical trial optional): AIDS-related

### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call encourages applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related call encourages investigators to submit research grant applications that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Dissemination and implementation research in health (R03): Aids-related

### **NIH: National Institute of Mental Health**

This Aids-related announcement supports research that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures and strategies to disseminate and implement evidence-based health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and

management, and quality of life improvement services into public health, clinical practice and community settings. Application budgets are limited to \$50,000 in direct costs per year for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research grants using the resources from the osteoarthritis initiative (R21): AIDS-related

### **NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases**

This AIDS-related funding opportunity encourages research focused on the use of the osteoarthritis initiative database, clinical data and images. Direct costs may not exceed USD 275,000 over a

two-year project period, with no more than USD 200,000 in any year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases**

This AIDS-related funding opportunity supports research focused on the use of the osteoarthritis initiative database, clinical data and images. Applications budgets are not limited,

but must reflect the needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professiona](#)



## Biomarkers: bridging paediatric and adult therapeutics (R21): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This encourages research that adapts adult biomarkers to children. Application budgets are limited to USD 275,000 in direct costs for a maximum project duration of two

years. No more than USD 200,000 may be requested in a single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Development of appropriate paediatric formulations and paediatric drug delivery systems (R03): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application budgets are limited to USD 50,000

per year in direct costs. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Development of appropriate paediatric formulations and paediatric drug delivery systems (R21): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application

budgets are limited to USD 275,000 over a two-year project period, with no more than USD 200,000 in direct costs per year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Development of appropriate paediatric formulations and paediatric drug delivery systems (R01): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application

budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Chemical discovery award (R21/R33): Aids-related

### **NIH: National Institute on Drug Abuse**

This Aids-related award supports the development of chemical probes that aid basic research investigations on substance use disorders or identify new lead chemical scaffolds with potential for structure activity relationship studies on SUDs. Direct costs are limited to USD 275,000 over a R21 two-year period, with a maximum of

USD 200,000 allowed in any single year. The R33 award phase will be limited to USD 250,000 in direct costs per year for a maximum period of three years. The total project period may not exceed four years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with

mental disorders. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Eradication of HIV-1 from central nervous system reservoirs (R01)

### **NIH: National Institute of Mental Health**

This supports applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system in the context of viral suppression. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Collaborative clinical vision project – resource center grant (UG1 clinical trial required): AIDS-related

### **NIH: National Eye Institute**

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource or safety-risk clinical trials. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Clinical vision research: chair's grant (UG1 clinical trial required): AIDS-related

### **NIH: National Eye Institute**

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. Application

budgets are not limited, but must reflect the actual needs of the project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required): AIDS-related

### **NIH: National Eye Institute**

This AIDS-related funding opportunity supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other demanding

clinical trials. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity supports research to deepen the knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency

departments and long range treatment. The combined budget for direct costs may not exceed USD 100,000 over two years and no more than USD 50,000 in direct costs may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related call supports research on the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and the development of prevention and treatment strategies.

Applications budgets are limited to USD 275,000 in direct costs for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity announcement supports research to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies. Application

budgets are not limited, but need to reflect actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Family-centred self-management of chronic conditions (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call encourages research that seeks to build the science of family-centred self-management in chronic conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Family-centred self-management of chronic conditions (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions. The combined budget for direct costs may not exceed USD

275,000. No more than USD 200,000 may be requested in a single year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Alcohol-induced effects on tissue injury and repair (R21): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related call supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are

limited to USD 275,000 over a two-year project period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Alcohol-induced effects on tissue injury and repair (R01): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related call supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are not limited but need to reflect the actual

needs of the project over a period of up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages research in formative basic behavioural and social science to better understand a single step in the care continuum or multiple steps in the HIV care continuum. Application budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Community partnerships to advance research (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages researchers to partner with community groups, using community engaged research methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Application budgets may not exceed USD 275,000 over two years and no more than USD 200,00 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Community partnerships to advance research (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages researchers to partner with community groups, using community engaged research methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call stimulates research utilising mobile health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. The combined budget for direct costs for the two-

year project period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call stimulates research utilising mobile health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. Application

budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Natural killer cells to induce immunological memory to prevent HIV infection (R01)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports multidisciplinary, hypothesis-driven research on natural killer cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be

induced by HIV vaccination. Application budgets are not limited but must reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## CREATE bio optimisation track for biologics (U01): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports the optimisation of potential therapeutic biotechnology products and biologics for disorders identified under the NINDS mission, and supports the further characterisation and optimisation of therapeutic leads that showed promise as a potential therapeutic

agent as evidenced by convincing animal proof-of-concept studies. Budgets should normally remain under USD 500,000 in direct costs in any given year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## CREATE bio development track – nonclinical and early-phase clinical development for biologics (U01 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related call supports the development of therapeutic biotechnology products and biologics for disorders that fall under the institute's mission. Applications should not exceed USD

2.5 million. The total project duration is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UH2/UH3 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports neuroscience investigators seeking to advance their small molecule drug discovery and development projects into the clinic. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Self-management for health in chronic conditions (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call supports research in self-management for health in chronic conditions. The combined budget for direct costs for the two-year project period may not

exceed USD 275,000. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Self-management for health in chronic conditions (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call supports research that seeks to build the science of self-management for health in chronic conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related announcement aims to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease- or

age-related cognitive decline. Grants are worth up to USD 275,000 over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related announcement aims to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Promoting research in basic neuroscience (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related call aims to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Underactive bladder and detrusor activity in ageing (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related funding opportunity supports basic, clinical or translational pilot or feasibility projects addressing underactive bladder and detrusor underactivity and its consequences in ageing and

in older persons. Grants are worth up to USD 100,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Underactive bladder and detrusor activity in ageing (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related opportunity supports basic, clinical or translational research on underactive bladder and detrusor underactivity and its consequences in ageing and in older persons.

Grants are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Underactive bladder and detrusor activity in ageing (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related funding opportunity supports basic, clinical or translational research on underactive bladder and detrusor underactivity, and the consequences in ageing and in older persons. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related grant aims to develop novel, robust assays to reveal changes in neuronal or glial function. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is four years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovation grants to nurture initial translational efforts (IGNITE) – assay development and therapeutic agent identification (R61/R33 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports AIDS-related research that develops in vitro or ex vivo assays and conducts iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders.

Grants are worth up to USD 750,000 each over three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Innovation grants to nurture initial translational efforts (IGNITE) – neurotherapeutic agent characterisation and in vivo efficacy studies (R61/R33 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to

warrant further development to treat neurological disorders. Funding is worth up to USD 750,000 per project for up to three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports efforts to translate scientific discoveries and engineering developments into methods that address problems in basic research to understand disease, or in applied research to detect and manage

disease. Application budgets are not limited but must reflect the needs of the project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Prevention research in mid-life adults (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports research on mid-life adults, those between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later

years. Grants are worth up to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



### Prevention research in mid-life adults (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports research on mid-life adults, between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age, and

prevent illness and disability in later years. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Novel biomarkers for the development of HIV incidence assays with improved specificity (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent from chronic

HIV infections. Grants are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professiona](#)



### Early-life factors and cancer development later in life (R03 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call stimulates research focused on the role of early-life factors in cancer development in later life. Awards are worth up to USD 100,000 each in

direct costs over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Early-life factors and cancer development later in life (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call stimulates research focused on the role of early-life factors in cancer development in later life. Awards are worth up to USD 275,000 each in

direct costs over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Early-life factors and cancer development later in life (R01 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call aims to stimulate research focused on the role of early-life factors in cancer development in later life. Application budgets are not limited but need to reflect the actual needs of the

proposed projects. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Pilot and feasibility clinical research grants in kidney diseases (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related funding opportunity supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney

diseases research. Grants are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Diet and physical activity assessment methodology (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related opportunity supports innovative research to enhance the quality of measurements of dietary intake and physical activity with a focus on AIDS. Application budgets are not limited but need to reflect the actual

costs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based

therapies for pain. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Harnessing big data to halt HIV (R01 clinical trial optional)

### **NIH: National Institute of Allergy and Infectious Diseases**

This promotes research that transforms understanding of HIV transmission, the HIV care continuum and HIV comorbidities using big data science. Application budgets are not limited but must reflect the actual needs of the

project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Direct

costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This AIDS-related opportunity supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or the development of needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial

databases. Funding is worth up to USD 200,000 per project over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## HIV/AIDS high priority drug abuse research (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports high priority research relevant to drug abuse and HIV and AIDS. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovative questions in symptom science and genomics (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science.

Application budgets are limited to USD 275,000 and no more than USD 200,000 may be requested in any single year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Innovative questions in symptom science and genomics (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified innovative questions in symptom and genomic nursing

science. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovation grants to nurture initial translational efforts – development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R61/R33): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This encourages development and validation of animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder, or clinically feasible pharmacodynamic markers for therapeutics designed to

treat neurological disease. Awards are worth up to USD 750,000 for three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Applying metabolomics to drive biomarker discovery in symptom science (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports projects on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. The

combined budget for direct costs excluding consortia facilities and administration costs for the maximum two-year project period may not exceed USD 275,000.



**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Applying metabolomics to drive biomarker discovery in symptom science (R01 clinical trial optional): AIDS-related

**NIH: National Institute of Nursing Research**

This AIDS-related opportunity encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding,

[Link to \\*Research Professional](#)

assessment and management of symptoms. The maximum project period is five years.

**Closing date: 07 May 19**

### Natural history of disorders identifiable by screening of newborns (R01 clinical trial optional): AIDS-related

**NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related call encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R21 clinical trial optional): AIDS-related

**NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring.

Application budgets are limited to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R01): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Multidisciplinary research in vulvodynia (R03): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to US\$100,000 over the

maximum period of two years. No more than US\$50,000 in direct costs may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Multidisciplinary research in vulvodynia (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to USD 275,000 over the

maximum period of two years. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Multidisciplinary research in vulvodynia (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Modelling of infectious disease agent study research projects (R01): Aids-related

### **NIH: National Institute of General Medical Sciences**

This Aids-related announcement supports innovative research that will develop and apply computational tools and methods for modelling interactions between infectious agents and their hosts, disease spread, prediction systems

and response strategies. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Improvement of animal models for stem-cell-based regenerative medicine (R21): Aids-related

### **NIH: Office of the Director**

This Aids-related announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are limited to

US\$275,000 over a two-year period, with no more than US\$200,000 in any year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Improvement of animal models for stem-cell-based regenerative medicine (R01): Aids-related

### **NIH: Office of the Director**

This Aids-related announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are not limited, but must reflect the actual needs of

the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Role of astrocytes and astrocytic networks in drug abuse (R21): Aids-related

### **NIH: National Institute on Drug Abuse**

This Aids-related announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application

budgets are limited to US\$275,000 in direct costs over a maximum period of two years. No more than US\$200,000 in direct costs may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Population health interventions: integrating individual and group level evidence (R21 clinical trial not allowed): AIDS-related

### **NIH: Office of the Director**

This AIDS-related call supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. The combined budget for direct

costs for the two year project period may not exceed USD 275,000. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Role of astrocytes and astrocytic networks in drug abuse (R01): Aids-related

### **NIH: National Institute on Drug Abuse**

This Aids-related announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Population health interventions: integrating individual and group level evidence (R01 clinical trials not allowed): AIDS-related

### **NIH: Office of the Director**

This AIDS-related funding opportunity supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Tailoring dental treatment for individuals with systemic diseases that compromise oral health (R21): Aids-related

### **NIH: National Institute of Dental and Craniofacial Research**

This Aids-related announcement aims to encourage developmental or exploratory clinical research related to addressing gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise

dental treatment guidelines tailored to patient needs. Application budgets are limited to US\$275,000 in direct costs over the maximum two year period. No more than US\$200,000 is allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Understanding factors in infancy and early childhood that influence obesity development (R01 clinical trial optional):

### AIDS-related

#### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related announcement seeks applications that propose to characterise or identify factors in early childhood that may increase or mitigate risk for obesity or excessive weight gain or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Exploratory grants in cancer epidemiology and genomics research (R21): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related funding opportunity supports research on cancer epidemiology, genomics and risk assessment. The combined budget for direct costs may not

exceed USD 275,000 over a maximum of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R21 clinical trial optional): AIDS-related

#### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement aims to establish a programme of research to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome.

Application budgets are limited to USD 275,000 in direct costs for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R03 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity aims to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are limited to

USD 50,000 in direct costs per year for the maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity aims to establish a programme of research to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement encourages preclinical research in model organisms of neurodevelopmental disorders. Application budgets are limited to

US\$499,999 per year over a period of up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity encourages applications from institutions that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities.

Application budgets are limited to USD 499,999 per year over a five-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Role of mobile genetic elements in cancer (R21): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related opportunity supports projects that investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR

retroelements, in cancer. Grants are worth up to USD 275,000 each for two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Role of mobile genetic elements in cancer (R01): AIDS-related

### **NIH: National Institutes of Health**

This Aids-related announcement encourages applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Metabolic reprogramming to improve immunotherapy (R21): Aids-related

### **NIH: National Cancer Institute**

This Aids-related announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the

tumour, the immune response, or both to improve cancer immunotherapy. Application budgets are limited to US\$275,000 over a maximum period of two years. No more than US\$200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Non-healing ulcerative wounds in ageing (R21): Aids-related

### **NIH: National Institute on Aging**

This Aids-related announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are limited to

US\$275,000 for a maximum period of two years. No more than US\$200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Metabolic reprogramming to improve immunotherapy (R01): Aids-related

### **NIH: National Cancer Institute**

This Aids-related announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this

information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Non-healing ulcerative wounds in ageing (R01): Aids-related

### **NIH: National Institute on Aging**

This Aids-related announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Mechanisms of cancer and treatment-related symptoms and toxicities (R21): Aids-related

### **NIH: National Cancer Institute**

This Aids-related announcement supports innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioural and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout

the cancer care trajectory. Application budgets are limited to US\$275,000, with no more than US\$200,000 allowed in any single year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Serious adverse drug reaction research (R21): Aids-related

### **NIH: National Human Genome Research Institute**

This R21 Aids-related funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Direct costs are limited to \$275,000 over a

two-year period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Serious adverse drug reaction research (R01): Aids-related

### **NIH: National Human Genome Research Institute**

This R01 Aids-related funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Application budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is four years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related funding opportunity supports the development of innovative interventions that improve cancer-related health behaviours across diverse racial or ethnic populations.

Application budgets are limited to USD 275,000 for up to two years

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Integrative research on polysubstance abuse and addiction (R21/R33 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related call aims to characterise how the neurobiological alterations, associated behaviours, and public health consequences arising from polysubstance use differ from those observed in single drug use. The R21 phase is worth up to USD 275,000

during a two-year period, and the R33 phase is worth up to USD 500,000 per year for a three-year period. The total project period may not exceed five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01): Aids-related

### **NIH: National Institute of Dental and Craniofacial Research**

This Aids-related announcement supports research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are not limited but need to reflect the

actual needs of the project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Safety and outcome measures of pain medications used in children and pregnant women (R03 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications and develop effective instruments or approaches to evaluate maternal and child

outcomes of pain medication treatments. Grants are worth up to USD 50,000 per year for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Safety and outcome measures of pain medications used in children and pregnant women (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain

medications and develop effective approaches to evaluate maternal and child outcomes of pain medication treatments. Grants are worth up to USD 275,000 for up to two years.





## Secondary analyses of alcohol and chronic disease (R03): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This Aids-related announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data.

Application budgets are limited to USD 50,000 in direct costs per year. The maximum project duration is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Engineering next-generation human nervous system microphysiological systems (R01): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related announcement aims to stimulate basic research to develop next-generation human cell-derived microphysiological systems with improved fidelity to complex human brain, spinal, peripheral nervous system and sensory end organ circuit physiology in vivo.

Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Secondary analyses of alcohol and chronic disease (R01): Aids-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This Aids-related announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project duration is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## High or medium priority AIDS research on non-AIDS-defining or AIDS-defining cancers (R21)

### **NIH: National Cancer Institute**

This call aims to advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immunodeficiency syndrome, particularly the non-AIDS defining malignancies which are

now a leading cause of death in HIV-infected individuals. Application budgets are worth up to USD 275,000 for a maximum period of two years. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## High or medium priority AIDS research on non-Aids-defining or Aids-defining cancers (R01)

### **NIH: National Cancer Institute**

This call aims to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immunodeficiency syndrome, particularly the non-AIDS defining malignancies which are

now a leading cause of death in HIV-infected individuals. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Symptom management in HIV-infected individuals with comorbid conditions (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call seeks research applications focused on developing, adapting and testing innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated Non-AIDS conditions and other comorbidities among

older adults with prolonged HIV infection. Grants are worth up to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call supports the development, adaptation and testing of innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated non-AIDS conditions and other comorbidities among older adults with prolonged HIV infection.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Basic and translational research on decision making in ageing and Alzheimer's disease (R01): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related call seeks applications for basic research to better characterise the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal ageing and Alzheimer's disease. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Trophoblast differentiation and function (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement supports research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the

immune system. Grants are worth up to USD 275,000 over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Trophoblast differentiation and function (R01): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This encourages applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Application budgets

are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Palliative care needs of individuals with rare advanced diseases and their family caregivers (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call seeks to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill

individuals and their family caregivers. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Improving individual and family outcomes through continuity and coordination of care in hospice (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality

coordination of care of individuals who are enrolled in hospice. Application budgets are worth up to USD 275,000 for a two-year project period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application budgets

are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Self-management interventions and technologies to sustain health and optimise functional capabilities (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call supports clinical research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities,

prevent or delay disabilities and navigate their environment. Application budgets are worth up to USD 275,000 for a period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Use of technology to enhance patient outcomes and prevent illness (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are worth up to USD 275,000 for a two-year period.

No more than USD 200,000 in direct costs may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)







## Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related funding opportunity supports research projects that increase the understanding of the clinical translational potential of metformin to delay deleterious ageing changes or to extend healthy human life span.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Tobacco use and HIV in low- and middle-income countries (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This supports exploratory or developmental research focused on tobacco use and human immunodeficiency virus infection in LMICs. Applications budgets are

limited to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Tobacco use and HIV in low- and middle-income countries (R01 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports research focused on tobacco use and human immunodeficiency virus infection in low- and-middle income countries. Application budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Exploratory analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R21): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related call supports studies employing secondary analysis of existing cohorts, data sets and biorepositories to explore clinically related issues on ageing changes influencing health across the lifespan, including diseases and disabilities in older persons.

Application budgets are worth up to USD 275,000 for a maximum period of two years. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Strengthening the HIV pre-exposure prophylaxis care continuum through behavioural, social and implementation science (R21 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages behavioural, social, and implementation science research for HIV prevention and treatment. The combined budget for

direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Strengthening the HIV pre-exposure prophylaxis care continuum through behavioural, social, and implementation science (R01 clinical trial optional)

### **NIH: National Institutes of Health**

This funding opportunity announcement encourages research designed to identify gaps in the pre-exposure prophylaxis care continuum, develop interventions to strengthen delivery, use and outcomes, and reduce racial and age-

related disparities in PrEP uptake and use. Application budgets are not limited.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Reducing health disparities among minority and underserved children (R01 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related funding opportunity encourages research that targets the reduction of health disparities among children. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project duration is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Chronic condition self-management in children and adolescents (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages research that aims to improve self-management and quality of life in children and adolescents with chronic conditions. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Basic mechanisms of brain development mediating substance use and dependence (R01): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related call supports applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behaviour and in substance use and

dependence. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Zika virus complications (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement provides support for research on the Zika virus and its complications.

Grants are worth up to USD 275,000 in direct costs over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity supports research focused on advancing understanding of mechanisms by which mental health affects HIV prevention and treatment in order to identify modifiable intervention targets; and developing and pilot testing expanded interventions to improve

both mental health and HIV outcomes. Application budgets are limited to USD 275,00 over the maximum combined period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity encourages applications focused on advancing understanding of mechanisms by which mental health affects HIV, and developing and testing expanded interventions to improve both mental health and HIV outcomes. Application budgets

are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Formative and pilot intervention research for prevention and treatment of HIV/AIDS (R34 clinical trial optional)

### **NIH: National Institute of Mental Health**

This supports formative research, intervention development, and pilot-testing of interventions for HIV prevention or treatment. Direct costs are limited to USD 450,000 over three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R21 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages research in formative basic behavioural and social science to better understand a single step in the care continuum or multiple steps in the HIV care continuum, and initial development and pilot tests of innovative

approaches for intervention. Application budgets are limited to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related call encourages implementation research projects designed in partnership with global and domestic service providers to achieve 90/90/90 goals for HIV/AIDS prevention and treatment.

Application budgets should not exceed USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related announcement encourages implementation research projects designed in partnership with global and domestic service providers to achieve 90/90/90 goals for HIV/AIDS prevention and treatment.

[Link to \\*Research Professional](#)

Application budgets are not limited but should reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**



## Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R21 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity announcement supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Direct costs are limited

to USD 275,000 over a two-year period, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Marijuana, prescription opioid, or prescription benzodiazepine drug use among older adults (R03): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity announcement supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Application budgets

are limited to USD 50,000 in direct costs per year. The total project period may not exceed two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity announcement supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Application budgets

are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Clinical studies of mental illness not involving clinical trials (collaborative R01): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity announcement supports collaborative clinical studies that do not involve treatment development, efficacy, or effectiveness trials. Application budgets are not limited

but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Exploratory and developmental research grant (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity announcement supports exploratory and developmental research projects in their early and conceptual stages. Direct costs are limited to USD 275,000 over a

maximum period of two years, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Promoting NICHD areas of research for HIV/AIDS in maternal and child health (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This aims to stimulate HIV/AIDS research that investigates the development and the prevention of the virus in pregnant women, children and adolescents.

Application budgets are not limited

[Link to \\*Research Professional](#)

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

## Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R21): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related call supports innovative research that improves the understanding of innate and adaptive immune dysregulation caused by type 2 diabetes mellitus and pre-diabetes that causes increased risk of tuberculosis in the context of HIV co-infection. The

combined budget for direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## HIV and hepatitis B co-infection – advancing HBV functional cure through clinical research (R01)

### **NIH: National Institutes of Health**

This aims to fill scientific gaps needed to inform HBV functional cure strategies and to advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R01): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related call supports innovative research that improves the understanding of innate and adaptive immune dysregulation caused by type mellitus and pre-diabetes that causes increased risk

of tuberculosis in the context of HIV co-infection. Application budgets are not limited but need to reflect the actual needs of the project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Small grants for secondary analyses of existing data sets and stored biospecimens (R03) AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports AIDS-related research that conducts secondary analyses of publicly available data sets or stored biospecimens funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Application budgets

are limited to USD 50,000 in direct costs per year for a maximum performance period of up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Imaging the persistent HIV reservoir (R01)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of imaging approaches to identify and characterise persistent HIV reservoirs in patients undergoing suppressive antiretroviral therapy. Application budgets are not limited

but need to reflect the actual needs of the proposed project over a period of up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Optimising HIV phylodynamics to target and interrogate clusters (R21)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports exploratory basic research to develop innovative phylodynamic approaches to identify and prioritise the most rapidly growing HIV transmission clusters within a given population of

individuals in near-real time. Applications budgets are limited to USD 275,000 in direct costs for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related call supports studies that aim to improve understanding of aspects of ageing through the lens of HIV infection and its treatment, as well as improve approaches for testing of HIV infection and management of HIV-

related complications in different populations and cultural settings. Combined budgets are worth up to USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related funding opportunity supports studies addressing HIV and ageing that aim to improve understanding of biological, clinical and socio-behavioural aspects of ageing through the lens of HIV infection. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)







## Ethical, legal and social implications of genomics research small research grant programme (R03): AIDS-related

### **NIH: National Human Genome Research Institute**

This supports small-scale AIDS-related studies on the ethical, legal and social implications of human genome research. Application budgets are limited to no more than USD 50,000 in direct costs per year.

The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Ethical, legal and social implications of genomics research exploratory/developmental research programme (R21): AIDS-related

### **NIH: National Human Genome Research Institute**

This supports AIDS-related studies on the ethical, legal and social implications of human genome research. Application budgets are limited to USD 275,000 in direct costs for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Ethical, legal and social implications of genomic research regular research programme (R01): AIDS-related

### **NIH: National Human Genome Research Institute**

This supports AIDS-related studies on the ethical, legal and social implications of human genome research. Application budgets are not limited but need to reflect the

actual needs of the proposed project over up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Using small molecules and molecular genetics to identify novel targets and mechanisms contributing to tumour immune evasion (R01): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related funding opportunity aims to stimulate research on the identification of new and novel targets and mechanisms involved in tumour immune evasion, which may be amenable to analysis by small molecules, pharmacological, or molecular genetics approaches.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Discovery of cell-based chemical probes for novel brain targets (R21): AIDS-related

### **NIH: National Institute of Mental Health**

This supports investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. Application budgets are limited to USD 275,000 over a

two-year period, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Synthetic biology for engineering (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related call supports research that advances the understanding and application of synthetic biology for human health. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum award project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Assay development and screening for discovery of chemical probes or therapeutic agents (R01): AIDS-related

### **NIH: National Cancer Institute**

This supports AIDS-related research in discovery and development of novel, small molecules for their potential use in studying disease treatment, and to generate new insight into the biology of relevant diseases and processes that are not yet drug targets. Application budgets

are not limited but need to reflect the actual needs of the proposed project, for a period of up to four years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NIBIB exploratory/developmental research grant programme (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related call supports exploratory or developmental research projects of interest to the National Institute of Biomedical Imaging and Bioengineering, that will lead to breakthroughs in development of innovative techniques, agents, methodologies,

models, or their applications. Application budgets may not exceed USD 275,000 in direct costs over a maximum two-year funding period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Secondary analyses of existing alcohol research data (R03) AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity supports the secondary analysis of existing data sets with the goal of enhancing the understanding of patterns of alcohol consumption, the epidemiology and aetiology, including genetics, of alcohol-related problems.

Applications budgets are limited to USD 50,000 per year. The total project period may not exceed two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Secondary analyses of existing alcohol research data (R01): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity supports analysis of recently collected data and findings in alcohol epidemiology, prevention and genetic research with a focus on prenatal alcohol exposure. Application budgets are not limited

but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Understanding and modifying temporal dynamics of coordinated neural activity (R21 clinical trial optional): AIDS- related

### **NIH: National Institute of Mental Health**

This AIDS-related call supports projects that test whether modifying electrophysiological patterns during behaviour can improve cognitive, affective, or social processing. The combined budget for direct costs for

the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Understanding and modifying temporal dynamics of coordinated neural activity (R01 clinical trial optional): AIDS- related

### **NIH: National Institute of Mental Health**

This AIDS-related call supports research to lay the groundwork for developing systems-level neuroscience interventions into treatments for cognitive, affective or social deficits in psychiatric disorders. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Research on the health of transgender and gender nonconforming populations (R21 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This supports research on the health of transgender and gender nonconforming people of all ages, with a focus on AIDS. Grants are worth up to USD 275,000 each for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research on the health of transgender and gender nonconforming populations (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related call supports research on the health of transgender and gender nonconforming people of all ages. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## New onset depressive symptoms in acute illness (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity encourages research on the aetiology of depressive symptoms that occur in the context of a sudden onset acute illness.

Application budgets are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## New onset depressive symptoms in acute illness (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related encourages research on the aetiology of depressive symptoms that occur in the context of a sudden onset acute illness. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Addressing chronic wound trajectories through social genomics research (R21: clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement supports clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The combined budget for direct costs for the two-year project period may not

exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports implementation of interventions that demonstrate improved HIV-related health outcomes including HIV testing, pre-exposure prophylaxis and antiretroviral therapies adherence and sustained viral suppression in communities at risk in the US. The

combined budget for direct costs for the two-year project period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year. The total project period may not exceed two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Addressing chronic wound trajectories through social genomics research (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related announcement supports clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports projects that translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalised populations in the US with a

substantial risk of HIV-infection and AIDS. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Fundamental science research on mind and body approaches (R21 clinical trial optional): AIDS-related

### **NIH: National Center for Complementary and Integrative Health**

This AIDS-related call investigates the fundamental science of mind and body approaches, body-based approaches, meditative exercise, art and music therapies, or integrative approaches combining several components. The combined budget

for direct costs for the two-year project period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Fundamental science research on mind and body approaches (R01 clinical trial optional): AIDS-related

### **NIH: National Center for Complementary and Integrative Health**

This AIDS-related call investigates the fundamental science of mind and body approaches, body-based approaches, meditative exercise, art and music therapies, or integrative approaches combining several components. Application budgets

are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Investigator-initiated clinical trials targeting diseases within the mission of NIDDK (R01 clinical trial required): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related call supports clinical trials to be conducted at no more than two clinical research centres. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## The application of big data analytics to drug abuse research (R01 clinical trial optional): AIDS related

### **NIH: National Institute on Drug Abuse**

This AIDS related call encourages the application of big data analytics to reveal deeper or novel insights into the biological and behavioural processes associated with substance

abuse and addiction. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)







## Advancing understanding, prevention, and management of infections transmitted from women to their infants (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This stimulates investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women

to their offspring. Grants are worth up to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Advancing understanding, prevention, and management of infections transmitted from women to their infants (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related call stimulates investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from

women to their offspring during pregnancy, labor and delivery and breastfeeding.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Exploratory or developmental research grant programme (parent R21 clinical trial required): AIDS-related

### **NIH: National Human Genome Research Institute**

This AIDS-related funding opportunity supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Direct costs are limited to USD 275,000 over a maximum

period of two years, with no more than USD 200,000 in direct costs allowed in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## NIMH exploratory/developmental research grant (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related funding opportunity supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects.

Grants are worth up to USD 275,000 over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Human subjects mechanistic and minimal risk studies (R01 clinical trial optional): AIDS-related

### **NIH: National Eye Institute**

This AIDS-related call encourages applications that seek to conduct studies of the visual system. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NIDCD clinical trials in communication disorders (R01 clinical trial required): AIDS-related

### **NIH: National Institute on Deafness and other Communication Disorders**

This AIDS-related announcement supports investigator initiated low risk clinical trials addressing the mission and research interests of the National Institute on Deafness and Other Communication Disorders. Application budgets are limited to

less than USD 500,000 in direct costs in any year. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NINDS exploratory neuroscience research grant (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related announcement supports exploratory and innovative research projects, which fall within

the mission of the National Institute of Neurological Disorders and



Stroke. Grants are worth up to USD 275,000 for two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call supports the development of innovative interventions that improve cancer-related health behaviours across diverse racial and ethnic populations. Direct costs are limited

to USD 275,000 over a period of up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



### Population health interventions – integrating individual and group level evidence (R01 clinical trial optional): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



### Population health interventions – integrating individual and group level evidence (R21 clinical trial optional): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve

health outcomes. Application budgets are limited to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Feasibility clinical trials of mind and body interventions for NCCIH high priority research topics (R34 clinical trial required): AIDS-related

### **NIH: National Center for Complementary and Integrative Health**

This AIDS-related announcement supports early-phase clinical trials of mind and body approaches for conditions that have been identified by the National Center for Complementary and Integrative Health as high priority research

topics. Application budgets are limited to USD 450,000 for up to three years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## NIBIB research project grant (R01 clinical trial required): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related announcement supports a discrete, specified, circumscribed project related to the programmatic interests of the National Institute of Biomedical Imaging and Bioengineering. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Obesity and asthma – awareness and self-management (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity aims to encourage research that examines the relationship between asthma, obesity and self-management. Application budgets are not limited

but should reflect the actual needs of the project. The maximum period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



### NICHD small grant programme (R03 clinical trial optional): AIDS-related

#### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related announcement supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are limited to USD 50,000 in direct costs

per year. The maximum project period is two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### NICHD research project grant (R01 clinical trial required): AIDS-related

#### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related funding opportunity supports clinical trials that fall within the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Application budgets are not limited but need to reflect

the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Research project grant (parent R01 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related funding opportunity supports projects related to the programmatic interests of one or more of the participating NIH institutes and centres based on their scientific missions. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professiona](#)



## End-of-life and palliative care health literacy – improving outcomes in serious, advanced illness (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call aims to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care health literacy in diverse settings and populations. Application budgets are not limited

but should reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Human subjects mechanistic and minimal risk studies (R21 clinical trial optional): AIDS-related

### **NIH: National Eye Institute**

This supports AIDS-related low-risk studies of the visual system. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative care health literacy: improving outcomes in serious, advanced illness (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related call stimulates research focused on identification of the key barriers to effective end-of-life and palliative care health literacy in diverse settings and populations. The combined budget for direct

costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related call supports clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases. Application budgets are not limited but need to reflect the actual needs of the

proposes project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Analytical validation of candidate biomarkers for neurological disease (U01 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports analytical validation of candidate biomarker measures or endpoints. Application budgets are not limited but must reflect the needs of the project. The

maximum funding period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related announcement seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Application budgets

must not exceed USD 500,000 per year in direct cost. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Cancer prevention and control clinical trials grant programme (R01 clinical trial required): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related announcement supports investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, or survivorship related to cancer.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports projects that implement early phase investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions. Application budgets are limited to less than USD 500,000

in direct costs per year. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This AIDS-related opportunity supports basic and translational research projects examining HIV infection, persistence, and comorbidities relevant to the the institute's study of diabetes and other endocrine and metabolic diseases, digestive diseases,

nutritional disorders, obesity, and kidney, urologic and haematologic diseases. The combined budget for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Understanding processes of recovery in the treatment of alcohol use disorder (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity supports the examination of processes of recovery and relapse in the treatment of alcohol use disorders. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports research to characterise the consequences of psychosocial stress on affective and cognitive functioning, or pain processing as it relates to opioid use disorder. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Disease mechanisms of prenatal and paediatric hydrocephalus (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports hypothesis-driven research of prenatal and paediatric hydrocephalus. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## NIDA small research grant programme (R03 clinical trial required): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are limited to USD 50,000 in direct costs

per year. The total project period may not exceed two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity supports innovative research characterising the consequences of psychosocial stress on affective and cognitive functioning and pain processing as it relates to opioid use disorder. The

combined budget for direct costs for the two-year project period may not exceed USD 275,000.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports research that develops or substantially modifies existing cutting-edge tools that will advance prenatal or paediatric hydrocephalus research. Funding is

worth up to USD 275,000 over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Developmentally tailored HIV prevention and care research for adolescents and young adults (R01 clinical trial optional)

### **NIH: National Institute of Mental Health**

This supports research focused on adolescents and emerging adults as it relates to HIV prevention and treatment. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.





## Clinical validation of a candidate biomarker for neurological disease (U01 clinical trial optional): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related opportunity supports rigorous clinical evaluation of a candidate biomarker using retrospective or prospective methods in a manner that is

consistent with the purpose of the biomarker. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity supports the study of sensitivity and tolerance mechanisms underlying the development of alcohol use

disorders. The award is worth up to USD 1.77 million for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Developmental pharmacodynamics and models of drug effects in paediatrics (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related opportunity supports multidisciplinary, investigator-initiated studies that increase and establish data on developmental pharmacodynamics

in the paediatric age groups. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Innovative therapies and tools for screenable disorders in newborns (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related opportunity supports research relevant to the development of therapeutic interventions for potentially fatal or

disabling conditions that have been identified through newborn screening. Funding is for five years.





## High priority HIV/AIDS research within the mission of the NIDDK (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This supports AIDS-focused basic, translational and clinical research on diabetes and other endocrine and metabolic diseases that also addresses high priority HIV/AIDS research priorities and aims to

improve people's health and quality of life. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Basic and translational oral health research related to HIV/AIDS (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This AIDS-related opportunity supports innovative and basic translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-

morbidities in the oral cavity. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Basic and translational oral health research related to HIV/AIDS (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This AIDS-related funding opportunity supports basic and translational exploratory research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in

the oral cavity. Application budgets are limited to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Improving patient adherence to treatment and prevention regimens to promote health (R01 clinical trial optional): AIDS-related

### **NIH: Office of the Director**

This supports research that addresses patient adherence to treatment and prevention regimens to promote health outcomes with a focus on AIDS. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Improving patient adherence to treatment and prevention regimens to promote health (R21 clinical trial optional) – AIDS-related

### **NIH: Office of the Director**

This supports research that addresses patient adherence to treatment and prevention regimens to promote health outcomes, with a focus on AIDS. Grants are worth up to USD 275,000 for a two-year

period, with no more than USD 200,000 in any single year.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Small research grants for establishing basic science-clinical collaborations to understand structural birth defects (R03 clinical trial not allowed): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

These AIDS-related grants promote the initial establishment of basic science-clinical collaboration by providing small grants to teams of basic scientists, physician scientists or clinicians. Grants are worth up to

USD 75,000 per year for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Small research grants for analyses of data for the Gabriella Miller Kids First Data Resource (R03 clinical trial not allowed): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related opportunity supports meritorious small research projects that involve analyses of genomic and phenotypic datasets that are part of the Kids First Data Resource or that could be added to

it. Funding is worth up to USD 200,000 for a maximum duration of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Precision imaging of oral lesions (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This AIDS-related opportunity supports the development, adaptation, optimisation and validation of accurate, reproducible, specific and sensitive imaging approaches to improve diagnosis, treatment and treatment monitoring

for diseases and conditions in the oral cavity and oropharynx. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Precision imaging of oral lesions (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Dental and Craniofacial Research**

This supports early-stage AIDS-related research projects that propose to adapt, optimise and validate existing imaging systems or develop new image-based methodologies and analytic tools capable of improving early detection, diagnosis and targeted

treatment of oral diseases and conditions. Grants are worth up to USD 275,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related opportunity encourages implementation research projects designed in partnership with global and domestic service providers to achieve 90/90/90 goals for HIV/AIDS prevention and treatment.

Grants are worth up to USD 275,000 each for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related opportunity supports research on the role of the gut microbiome in regulating metabolism and reproduction and its impact on fertility status with a

focus on AIDS. Grants are worth up to USD 275,000 for up to two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional): AIDS-related

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This AIDS-related opportunity supports research related to the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal, hypothalamo-pituitary-adrenal and hypothalamo-pituitary-thyroid axes

in the brain. Budgets are limited to USD 499,999 in direct costs per year for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Vision research epidemiology grant (UG1 clinical trial not allowed): AIDS-related

### **NIH: National Eye Institute**

This supports AIDS-related epidemiologic studies that use creative and innovative approaches to studying vision diseases and disorders with high public impact, to inform prevention and treatment strategies as well as basic sciences

research. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of alcohol or drugs singly or in

combination. Grants are each worth up to USD 50,000 per year for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. Grants are each worth up to USD 275,000 for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related opportunity supports translational and clinical studies using a variety of probiotic and prebiotic carriers to generate measurable functional evidence for the safe and effective use of these carriers in maintaining health or

preventing and treating diseases. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed): AIDS-related

### **NIH: National Institute of Mental Health**

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through

genome-wide association or sequencing studies. Funding is for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Applying a biopsychosocial perspective to self-management of chronic pain (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to self-management of chronic pain with a focus on AIDS. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Biobehavioural basis of chronic pain (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports studies on the biobehavioural basis of chronic pain with a focus on the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the

individual's chronic pain experience. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Applying a biopsychosocial perspective to self-management of chronic pain (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to self-management of chronic pain with a focus on AIDS. Grants are worth up to USD 275,000 for two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



### Biobehavioural basis of chronic pain (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports AIDS-related research that focuses on the individual phenotype, genotype and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience.

Grants are worth up to USD 275,000 each over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports AIDS-related research that aims to improve the understanding of Fc-dependent, antibody-mediated killing of pathogen-infected or otherwise dysregulated host cells. Grants are

each worth up to USD 275,000 over a maximum of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

### Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions, with a

focus on AIDS. The project may last up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This supports AIDS-related research focused on the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions. Grants are

worth up to USD 275,000 each over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related

### **NIH: National Institute on Deafness and other Communication Disorders**

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative care approaches to advanced signs and symptoms (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports the examination of the multi-dimensional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. The project may last up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related

### **NIH: National Institute on Deafness and other Communication Disorders**

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. Grants are worth up to USD 275,000 for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative care approaches to advanced signs and symptoms (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports the examination of the multi-dimensional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. Grants are worth up to USD 275,000 each over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Engaging men in HIV testing, prevention and care (R01 clinical trial optional)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development and testing of strategies to increase the engagement of men in HIV prevention and care within global settings and among domestic populations who have lower rates of

engagement and retention in HIV prevention and care. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Engaging men in HIV testing, prevention and care (R21 clinical trial optional)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development and testing of strategies to increase the engagement of men in HIV prevention and care within global settings and among domestic populations who have lower rates of engagement and retention in HIV

prevention and care. Grants are worth up to USD 275,000 for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian or Alaska Native individuals with advanced illness

and their families and communities. Funding is for five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian and Alaska Native individuals with advanced illness and their families and communities.

Grants are worth up to USD 275,000 each over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Clinical trial planning grant (R34 clinical trial required): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity enables researchers to develop and finalise plans for the design and execution of investigator-initiated clinical trials that are highly relevant to nursing research. Grants are

worth up to USD 250,000 each over two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Processing and presentation of non-conventional MHC ligands (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Processing and presentation of non-conventional MHC ligands (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. Grants are worth up to USD 275,000 each for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





## Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of research. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Telomeres in wellness and disease – a biobehavioural approach (R21 clinical trial optional): AIDS-related

### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of

research. Grants are worth up to USD 275,000 each for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Research project grant (parent R01 basic experimental studies with humans required): AIDS-related

### **NIH: National Institute on Aging**

This AIDS-related opportunity supports discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)





**Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related**

**NIH: National Institute on Aging**

This AIDS-related opportunity supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Direct costs are limited to USD

275,000 over a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

**Research to advance hepatitis B virus cure – HIV/HBV co-infection and HBV mono-infection (R01 clinical trial not allowed): AIDS-related**

**NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related opportunity supports innovative basic, translational and clinical research to identify and address the challenges to achieving HBV cure in the

presence or absence of HIV. The maximum grant period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

**Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trial not allowed): AIDS-related**

**NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases including histoplasmosis and blastomycosis.

The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases, including histoplasmosis and blastomycosis.

Grants are worth up to USD 275,000 each for a maximum period of two years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Bioengineering research grants (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related call supports collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

This AIDS-related call encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The

maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Exploratory/developmental bioengineering research grants (R21 clinical trial not allowed): AIDS-related

### **NIH: National Cancer Institute**

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or

clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Progression markers for cognitive impairment in Parkinson's disease dementia (R01 clinical trial not allowed): AIDS-related

### **NIH: National Institute on Aging**

This supports AIDS-related research to identify biomarkers for onset and progression of cognitive impairment in Parkinson's disease through Parkinson's disease dementia. The budget for fiscal year 2019 is USD 5

million, to fund five to seven awards. The maximum project period is five years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)

## Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinical trial not allowed): AIDS-related

### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related call supports prospective observational comparative effectiveness research evaluating preventive strategies, diagnostic approaches or interventions including drugs, biologics and devices or surgical,

behavioural and rehabilitation therapies. The maximum project period is seven years.

**Closing date: 07 May 19**

[Link to \\*Research Professional](#)



## Secondary analyses of existing datasets in heart, lung and blood diseases and sleep disorders (R21): AIDS-related

### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call aims to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioural research in areas

relevant to the NHLBI mission. Application budgets are worth up to USD 150,000 for a two year period. No more than USD 75,000 is allowed in any single year.

**Closing date: 08 May 19**

[Link to \\*Research Professional](#)

## Quantitative imaging tools and methods for cancer therapy response assessment (UG3/UH3 clinical trial optional)

### **NIH: National Cancer Institute**

This supports research projects that address the development, optimisation and validation of quantitative imaging software tools and methods for prediction and measurement of response to cancer therapies. Application budgets are

worth up to USD 500,000 per year for up to five years.

**Closing date: 09 May 19**

[Link to \\*Research Professional](#)

## NIAID clinical trial planning grant (R34)

### **NIH: National Institute of Allergy and Infectious Diseases**

This announcement supports applications that propose the complete planning, design and preparation of the documentation necessary for the implementation of investigator-initiated clinical trials.

Application budgets are limited to US\$150,000 in direct costs and the maximum project period is one year.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)



## NIAID clinical trial implementation cooperative agreement (U01 clinical trial required)

### **NIH: National Institute of Allergy and Infectious Diseases**

This announcement supports cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Application budgets are not limited but must

reflect the actual needs of the proposed project. The maximum funding period is five years.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)



## NIAID clinical trial implementation grant (R01)

### **NIH: National Institute of Allergy and Infectious Diseases**

This R01 funding opportunity announcement encourages applications for implementation of investigator-initiated, non-high-risk clinical trials. Application budgets are not limited but must reflect the actual needs of the proposed project.

The maximum funding period is five years.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)



## Single-site investigator-initiated clinical trials (R61/R33: clinical trial required): AIDS-related

### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call supports development and implementation of phase II and beyond investigator-initiated single-site clinical trials relevant to the research mission of the National Heart, Lung and Blood Institute. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)





### Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related

#### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related announcement supports the development and implementation of a clinical coordinating centre for investigator-initiated multi-site phase II and beyond clinical trials that are relevant to the research mission of the National Heart, Lung and Blood

Institute. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)

### Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required): AIDS-related

#### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call supports the implementation of a collaborating data coordinating centre for investigator-initiated multi-site phase II and beyond clinical trials that are relevant to the research mission of the National Heart, Lung, and Blood Institute. Application

budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)

### Administrative supplement for research on bioethical issues (admin supp clinical trial optional)

#### **NIH: National Cancer Institute**

This supports current holders of specific types of National Institutes of Health grants in conducting research on the bioethical, legal and societal implications of a range of issues and trends. Supplements are worth up to USD 100,000 in direct

costs per project over a maximum period of one year.

**Closing date: 13 May 19**

[Link to \\*Research Professional](#)





## Administrative supplements for geospatial, multilevel and contextual approaches in cancer control and population sciences

### **NIH: National Cancer Institute**

This supports administrative supplement applications that address the complex nature of cancer occurrence and outcomes by examining the role of two or more etiologic agents at multiple levels, one of which must include social or built environmental factors

measured at the geographic level. Awards are worth up to USD 150,000 each for one year.

**Closing date: 15 May 19**

[Link to \\*Research Professional](#)

## Administrative supplements to promote data sharing in cancer epidemiology studies

### **NIH: National Cancer Institute**

This enables current National Institutes of Health awardees to prepare and submit cancer epidemiology data into NIH or NCI-supported data repositories. Supplements are worth up to USD

150,000 per project over a maximum period of one calendar year.

**Closing date: 15 May 19**

[Link to \\*Research Professional](#)

## Functional RNA modifications environment and disease (R01 clinical trial not allowed)

### **NIH: National Institute of Environmental Health Sciences**

This supports research on how environmental exposures are associated and involved with the functional activities of RNA modifications and pathways that may be modified or misregulated, associated with adverse health outcomes or be useful as biomarkers

of exposure or exposure-induced pathologies. Grants are worth up to USD 250,000 each per year for a maximum period of five years.

**Closing date: 16 May 19**

[Link to \\*Research Professional](#)



## Functional RNA modifications environment and disease (R21 clinical trial not allowed)

### **NIH: National Institute of Environmental Health Sciences**

This supports innovative, high risk, high reward research addressing how environmental exposures impact cellular regulation involving chemical modifications of proteins, DNA and RNA nucleoside moieties.

Grants are worth up to USD 150,000 each per year for a maximum period of two years.

**Closing date: 16 May 19**

[Link to \\*Research Professional](#)

## BLOODSAFE – research to enhance availability of safe blood for patients with severe anaemia and haemorrhagic conditions in low or lower-middle income countries in sub-Saharan Africa (UG3/UH3 clinical trial optional)

### **NIH: National Heart, Lung and Blood Institute**

This supports projects that enhance the availability and delivery of safe blood to be used for transfusion in patients from low or lower-middle income countries in Sub-Saharan Africa. Three grants, worth a

maximum of approximately USD 3m each over six years, are available.

**Closing date: 20 May 19**

[Link to \\*Research Professional](#)

## International research in infectious diseases including AIDS (R01)

### **NIH: National Institute of Allergy and Infectious Diseases**

This encourages applications, from organisations or institutions in eligible foreign countries, that propose research related to infectious diseases that are of interest or importance to that country with the intent of local

scientific expertise. Applications may request a budget of up to USD 125,000 per year in direct costs for a maximum period of a five years.

**Closing date: 22 May 19**

[Link to \\*Research Professional](#)



## Innovative research in cancer nanotechnology (R01)

### **NIH: National Cancer Institute**

These support the development of innovative research projects in cancer nanotechnology. Application budgets are limited to USD 450,000 in direct costs per year. The

maximum project period is five years.

**Closing date: 23 May 19**

[Link to \\*Research Professional](#)

## Collaborative clinical vision project – resource center grant (UG1 clinical trial required)

### **NIH: National Eye Institute**

This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource or safety-risk clinical trials. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 25 May 19**

[Link to \\*Research Professional](#)

## Clinical vision research: chair's grant (UG1 clinical trial required)

### **NIH: National Eye Institute**

This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. Application budgets are not

limited, but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 25 May 19**

[Link to \\*Research Professional](#)

## Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required)

### **NIH: National Eye Institute**

This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex, high resource or safety-risk clinical trials. Application budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 25 May 19**

[Link to \\*Research Professional](#)



## Genomic community resources (U24)

### **NIH: National Human Genome Research Institute**

This supports the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. Application budgets are not limited,

but should reflect the needs of the proposed project over a maximum period of five years.

**Closing date: 25 May 19**

[Link to \\*Research Professional](#)

## Vision research epidemiology grant (UG1 clinical trial not allowed)

### **NIH: National Eye Institute**

This supports epidemiologic studies that use creative and innovative approaches to studying vision diseases and disorders with high public impact, to inform prevention and treatment strategies as well as

basic sciences research. Funding is for up to five years.

**Closing date: 25 May 19**

[Link to \\*Research Professional](#)

## Advanced development and validation of emerging biospecimen science technologies for basic and clinical cancer research (R33 clinical trial not allowed)

### **NIH: National Cancer Institute**

This supports exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care.

Application budgets are limited to USD 300,000 in direct costs per year for up to three years.

**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

## Innovative biospecimen science technologies for basic and clinical cancer research (R21 clinical trial not allowed)

### **NIH: National Cancer Institute**

This supports exploratory research projects focused on the early-stage

development of highly innovative technologies that improve the



quality of the samples used for cancer research or clinical care. Application budgets are limited to USD 400,000 over a maximum period of three years.

**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

---

### Advanced development and validation of emerging molecular and cellular analysis technologies for basic and clinical cancer research (R33 clinical trial not allowed)

**NIH: National Cancer Institute**

This seeks exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology

for basic or clinical cancer research. Application budgets are limited to USD 300,000 per year for up to three years.

**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

---

### Innovative molecular and cellular analysis technologies for basic and clinical cancer research (R21)

**NIH: National Cancer Institute**

This supports exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. Application budgets

are worth up to USD 400,000 over a maximum period of three years.

**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

---

### Revisions for incorporation of novel NCI-supported technology to accelerate cancer research (R01 clinical trial optional)

**NIH: National Cancer Institute**

This encourages revision applications from currently funded NCI R01 research projects proposing to expand upon the original research questions or otherwise accelerate

progress for the parent study. Grants are worth up to USD 150,000 each per year for a maximum period of two years.



**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

←—————→

**Revisions for incorporation of novel NCI-supported technology to accelerate cancer research (U01 clinical trial optional)**

**NIH: National Cancer Institute**

This encourages revision applications from currently funded NCI U01 research projects proposing to expand upon the original research questions or otherwise accelerate progress for the parent study. Grants are worth up to USD 150,000 each

per year for a maximum period of two years.

**Closing date: 28 May 19**

[Link to \\*Research Professional](#)

←—————→

**Perception and cognition research to inform cancer image interpretation (R21 clinical trial optional)**

**NIH: National Cancer Institute**

This supports research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and

diagnosis. Grants are worth up to 275,000 each over two years.

**Closing date: 30 May 19**

[Link to \\*Research Professional](#)

←—————→

**Perception and cognition research to inform cancer image perception (R01 clinical trial optional)**

**NIH: National Cancer Institute**

This supports research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology to improve the

accuracy of cancer detection and diagnosis. Funding is for five years.

**Closing date: 30 May 19**

[Link to \\*Research Professional](#)



## NCCIH mind and body clinical trial cooperative agreement (U01)

### **NIH: National Center for Complementary and Integrative Health**

This supports investigator-initiated clinical trials of mind and body interventions to be used in future multi-site trials. Application budgets are not limited but need to reflect

the actual needs of the proposed project.

**Closing date: 31 May 19**

[Link to \\*Research Professional](#)

## Serious adverse drug reaction research (R21)

### **NIH: National Human Genome Research Institute**

This R21 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Direct costs are limited to \$275,000 over a two-

year period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is two years.

**Closing date: 03 Jun 19**

[Link to \\*Research Professional](#)

## Serious adverse drug reaction research (R01)

### **NIH: National Human Genome Research Institute**

This R01 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Application budgets are not limited, but must

reflect the actual needs of the project. The maximum project period is four years.

**Closing date: 03 Jun 19**

[Link to \\*Research Professional](#)

## Role of epitranscriptomics in development and disease (R01 clinical trial not allowed)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and

disease states and conditions relevant to the participating institutes. Grants are worth up to







## Diet and physical activity assessment methodology (R01 clinical trial not allowed)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This supports innovative research to enhance the quality of measurements of dietary intake and physical activity. Application budgets are not limited but need to reflect the actual costs of the

proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## International research collaboration on drug abuse and addiction research (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Application budgets are not limited but must reflect the actual needs of the proposed project.

The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Bioengineering research grants (R01 clinical trial required)

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

These support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This aims to advance identification of male-female differences in drug and alcohol research outcomes and to advance research specific to women or highly relevant to women. Funding is for five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Bioengineering research partnerships (U01 clinical trial required)

### **NIH: National Institute of Biomedical Imaging and Bioengineering**

These support bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important

biomedical problems. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Ethical, legal and social implications of genomic research regular research programme (R01)

### **NIH: National Human Genome Research Institute**

This supports studies on the ethical, legal and social implications of human genome research.

Application budgets are not limited but need to reflect the actual needs

of the proposed project over up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This aims to improve understanding of the causes of high priority diseases in the US and mitigate health disparities. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research project grant (parent R01 clinical trial required)

### **NIH: National Institutes of Health**

This supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigators. Application budgets

need to reflect the actual needs of the proposed project. Funding is for five years.



**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01)

**NIH: National Institute on Drug Abuse**

This announcement encourages basic functional genomic research that identifies genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders. Applications budgets are

not limited, but must reflect the needs of the project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### Neuroscience research on drug abuse (R01 clinical trial optional)

**NIH: National Institute on Drug Abuse**

This supports research to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal and relapse

to chronic substance abuse. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### Nutrition and alcohol-related health outcomes (R01)

**NIH: National Institute on Alcohol Abuse and Alcoholism**

This supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Health promotion among racial and ethnic minority males (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to stimulate and expand research in the health of minority men. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

The aim is to encourage research on the effects of public policies of health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Application budgets are not limited

but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Epidemiology and prevention in alcohol research (R01 clinical trial optional)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This supports research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms and alcohol use disorders. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Genetic susceptibility and variability of human structural birth defects (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports innovative applications that will inform

understanding of structural birth defects through the use of animal



models in conjunction with translational or clinical approaches. Grants are worth up to USD 499,999 per year for projects of up to five years in duration.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### NLM research grants in biomedical informatics and data science (R01 clinical trial optional)

#### **NIH: National Library of Medicine**

This supports innovative research and development in biomedical informatics and data science. Grants are worth up to USD 250,000 each

per year over a maximum period of four years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### Investigations on primary immunodeficiency diseases/inborn errors of immunity (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports projects aiming to advance the discovery, characterisation and treatment of primary immunodeficiency diseases. Funding is for five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional)

#### **NIH: Office of the Director**

This supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Research to advance vaccine safety (R01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that will contribute to the overall understanding of vaccine safety. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01)

### **NIH: National Institute on Aging**

This supports applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on ageing changes influencing health across the lifespan, and on diseases and disabilities in older persons.

Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Drug discovery for nervous system disorders (R01 clinical trials not allowed)

### **NIH: National Institute of Mental Health**

This supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Alzheimer's drug development programme (U01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease, slow its progression or treat its cognitive and behavioural symptoms. Funding is worth up to

USD 1 million per project per year for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research on autism spectrum disorders (R01 clinical trial optional)

### **NIH: National Institute of Mental Health**

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Application budgets are not limited, but must

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Mechanisms of alcohol-associated cancers (R01)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This supports research that investigates cellular and molecular mechanisms by which alcohol increases cancer risk. Application budgets are not limited, but must reflect the actual needs of the

project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## NINDS exploratory clinical trials (U01 clinical trial required)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports investigator-initiated exploratory clinical trials within the mission and research interests of the National Institute of Neurological

Disorders and Stroke. Application budgets are not limited but must reflect the actual needs of the



project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### **NINDS efficacy clinical trials (U01 clinical trial required)**

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke. Application budgets are not limited, but need to reflect the actual needs of the project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### **Novel biomarkers for the development of HIV incidence assays with improved specificity (R01 clinical trial optional)**

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguished recent from chronic infections. Application budgets are not limited but need to reflect the

actual needs of the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

### **Hearing health care for adults – improving access and affordability (R01 clinical trial optional)**

#### **NIH: National Institute on Deafness and other Communication Disorders**

This supports research on hearing healthcare in adults in support of improving access and affordability. Application budgets are not limited, but must reflect the actual needs of

the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This announcement encourages preclinical research in model organisms of neurodevelopmental disorders. Application budgets are

limited to US\$499,999 per year over a period of up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Obesity and asthma – awareness and self-management (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to encourage research that examines the relationship between asthma, obesity and self-management. Application budgets are not limited but should reflect the actual needs of the project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Cellular and molecular biology of complex brain disorders (R01)

### **NIH: National Institute of Mental Health**

This encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. Application budgets are not limited but must

reflect the actual needs of the proposed project. The total project period may not exceed five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Development of appropriate paediatric formulations and paediatric drug delivery systems (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application budgets are not limited, but should

reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed)

### **NIH: National Institute of Mental Health**

This aims to develop novel, robust assays to reveal changes in neuronal or glial function. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is four years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 18. Application budgets are not limited, but need to reflect actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Health tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to stimulate research utilising mobile health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. Application budgets are not limited,

but need to reflect actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## NeuroNEXT clinical trials (U01 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This invites applications for exploratory clinical trials of investigational agents that may contribute to the justification for designing a future trial, for biomarker validation studies or for proof of mechanism clinical studies.

Application budgets are not limited, but need to reflect actual needs of the project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Mechanisms mediating osteoarthritis in ageing (R01)

### **NIH: National Institute on Aging**

This announcement encourages and accelerates the characterisation of new or underutilised models and the testing of hypotheses that will lead to an improved understanding of the mechanisms mediating osteoarthritic progression.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Discovery of in vivo chemical probes for novel brain targets (R01)

### **NIH: National Institute of Mental Health**

This supports investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings such as

playgrounds and nursing homes. Application budgets are not limited, but must reflect the actual needs of the project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports studies addressing HIV and ageing that aim to improve understanding of biological, clinical and socio-behavioural aspects of ageing through the lens of HIV infection and its treatment.

Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Juvenile protective factors and their effects on ageing (R01)

### **NIH: National Institute on Aging**

This call supports descriptive studies identifying putative juvenile protective factors, experimental studies testing hypotheses about their effects on ageing and translational studies exploring the potential risks and benefits of maintaining or modulating the level

of juvenile protective factors in adult life. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This encourages transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis

and survival. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This supports novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Application budgets are not limited, but must reflect the actual needs of the

project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Application budgets must not exceed USD 500,000 per

year in direct cost. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Biomarkers for diabetes, digestive, kidney and urologic diseases using biosamples from the NIDDK repository (R01)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This supports assays and data analysis of repository-held samples for studies focused on a disease relevant to the institute. Application budgets are limited to USD 250,000

in direct costs per year for a maximum of three years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed)

### **NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases**

These support research focused on the use of the osteoarthritis initiative database, clinical data and images. Applications budgets are not limited, but must reflect the needs of

the project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Advancing the science of geriatric palliative care (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports research focused on palliative care in geriatric populations. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed)

### **NIH: National Institute of Mental Health**

This supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through

genome-wide association or sequencing studies. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed)

### **NIH: National Institute of Mental Health**

This supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with

mental disorders. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports research to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies. Application budgets are not limited, but need to

reflect actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Family-centred self-management of chronic conditions (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This encourages research that seeks to build the science of family-centred self-management in chronic conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Alcohol-induced effects on tissue injury and repair (R01)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are not limited but need to

reflect the actual needs of the project over a period of up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Community partnerships to advance research (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This encourages researchers to partner with community groups, using community engaged research methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Clinical studies of mental illness not involving clinical trials (collaborative R01)

### **NIH: National Institute of Mental Health**

This supports collaborative clinical studies that do not involve treatment development, efficacy, or effectiveness trials. Application budgets are not limited but need to

reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## StrokeNet clinical trials and biomarker studies for stroke treatment, recovery and prevention (U01 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This encourages multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker- or outcome measure validation studies that are immediately preparatory to trials in stroke

prevention, treatment and recovery. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Collaborative research projects to enhance applicability of mammalian models for translational research (collaborative R01)

### **NIH: National Cancer Institute**

This supports collaborative projects from multidisciplinary teams to expand, improve, or transform the utility of mammalian cancer and tumour models for translational research. Application budgets are limited to USD 450,000 direct costs

per year. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research projects to enhance applicability of mammalian models for translational research (R01)

### **NIH: National Cancer Institute**

This supports research demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients'

benefit. Application budgets are limited to USD 450,000 in direct costs per year for a maximum of five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research on chronic overlapping pain conditions (R01)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports epidemiological, clinical and translational research that will increase understanding of the presence of multiple chronic

pain conditions in subjects with pain. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Self-management for health in chronic conditions (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports research that seeks to build the science of self-management for health in chronic

conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project.





## Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This supports efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect,

prevent and manage disease. Application budgets are not limited but must reflect the needs of the project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Prevention research in mid-life adults (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports research on mid-life adults, between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age, and prevent illness

and disability in later years. Funding is for up to five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Early-life factors and cancer development later in life (R01 clinical trial not allowed)

### **NIH: National Cancer Institute**

This aims to stimulates research focused on the role of early-life factors in cancer development in later life. Application budgets are not limited but need to reflect the actual needs of the proposed projects. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Achieving tissue robustness through harnessing immune system plasticity (R01 clinical trial not allowed)

### **NIH: National Institute of Dental and Craniofacial Research**

This supports state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and

craniofacial diseases. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based

therapies for pain. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Late stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial required)

### **NIH: National Institute on Aging**

This supports the development and implementation of late stage clinical trials of promising pharmacological and non-pharmacological

interventions in individuals with age-related cognitive decline and across the Alzheimer's disease spectrum from pre-symptomatic to





## Diet and physical activity assessment methodology (R01)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This announcement aims to enhance the quality of measurements of dietary intake and physical activity. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This aims to establish a programme of research to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Role of mobile genetic elements in cancer (R01)

### **NIH: National Institutes of Health**

This R01 funding opportunity announcement aims to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Metabolic reprogramming to improve immunotherapy (R01)

### **NIH: National Cancer Institute**

This announcement aims to generate a mechanistic understanding of the

metabolic processes that support robust anti-tumor immune



responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the tumour, the immune response, or

both to improve cancer immunotherapy.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Non-healing ulcerative wounds in ageing (R01)

### **NIH: National Institute on Aging**

This announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are not limited but need to reflect

the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R01)

### **NIH: National Institute of Allergy and Infectious Diseases**

This R01 funding opportunity announcement supports research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. Application budgets are not

limited but must reflect the needs of the project. The maximum funding period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Gene fusion in paediatric sarcomas (R01)

### **NIH: National Cancer Institute**

This R01 funding opportunity announcement encourages applications that explore the molecular biology of paediatric sarcomas to elucidate molecular mechanisms by which fusion genes and the resulting protein products

drive tumorigenesis and cancer progression. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.







## Safety and outcome measures of pain medications used in children and pregnant women (R01 clinical trial optional)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations and develop effective instruments or approaches to assess and evaluate maternal and child

outcomes of pain medication treatments. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Metabolic contributions to the neurocognitive complications of diabetes: ancillary studies (R01 clinical trial optional)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This supports human studies aiming to elucidate the aetiology and pathogenesis of the increased risk for neurocognitive impairment associated with type two diabetes. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for aging-related conditions (R01)

### **NIH: National Institute on Aging**

This supports basic and translational studies on ApoE2 and other variants to improve understanding of physiologic and cellular differences attributable to the ApoE e2 allele, versus other ApoE alleles, and how they mediate ApoE e2's differential effects on longevity and risk for age-

related conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Assay development and screening to discover therapeutic or imaging agents for diseases of interest to the NIDDK (R01)

### **NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

This aims to to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the NIDDK. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Engineering next-generation human nervous system microphysiological systems (R01)

### **NIH: National Institute of Mental Health**

This announcement aims to stimulate basic research to develop next-generation human cell-derived microphysiological systems with improved fidelity to complex human brain, spinal, peripheral nervous system and sensory end organ circuit physiology in vivo.

Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Secondary analyses of alcohol and chronic disease (R01)

### **NIH: National Institute on Alcohol Abuse and Alcoholism**

This announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project duration is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports the development, adaptation and testing of innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated non-AIDS conditions and other comorbidities among older adults with prolonged HIV infection. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Trophoblast differentiation and function (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This encourages applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Application budgets are not limited but need to reflect

the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Palliative care needs of individuals with rare advanced diseases and their family caregivers (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This seeks to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Improving individual and family outcomes through continuity and coordination of care in hospice (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality coordination of care of individuals who are

enrolled in hospice. Applications budgets are not limited but need to reflect the actual need of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application budgets

are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Self-management interventions and technologies to sustain health and optimise functional capabilities (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities, prevent or delay disabilities and navigate their environment.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Use of technology to enhance patient outcomes and prevent illness (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Improving quality of care and quality of life for persons with Alzheimer's disease and related dementias at the end of life (R01: clinical trial optional)

### **NIH: National Institute on Aging**

This aims to address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimer's disease and related dementias and their families. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Dynamic interactions between systemic or non-neuronal systems and the brain in ageing and in Alzheimer's disease (R01)

### **NIH: National Institute on Aging**

This supports research projects on the role of ageing-related changes in systemic, peripheral, and non-neuronal factors individually or in combination to the pathogenesis,

presentation, and progression of Alzheimer's disease.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Integrative research to understand the impact of sex differences on the molecular determinants of Alzheimer's disease risk and responsiveness to treatment (R01)

### **NIH: National Institute on Aging**

This seeks applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain ageing and phenotypes of Alzheimer's disease risk and on the responsiveness to pharmacologic and non-

pharmacologic interventions. Application budgets are worth up to USD 750,000 per year for a maximum period of five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer's disease (R01)

### **NIH: National Institute on Aging**

This seeks applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias with proof-of-concept efficacy studies in cell-based models,

animal models and humans. Application budgets are worth up to USD 500,000 per year for maximum period of five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Role of age-associated metabolic changes in Alzheimer's disease (R01)

### **NIH: National Institute on Aging**

This seeks innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Clarifying the relationship between delirium and Alzheimer's disease and related dementias (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This aims to clarify the relationship between delirium and Alzheimer's disease and related dementias. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Selective cell and network vulnerability in ageing and Alzheimer's disease (R01 clinical trial not allowed)

### **NIH: National Institute on Aging**

This aims to define and characterise neural cell populations, neural circuits and brain networks and regions that are vulnerable to brain ageing and Alzheimer's disease. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Leveraging existing cohort studies to clarify risk and protective factors for Alzheimer's disease and related dementias (R01)

### **NIH: National Institute on Aging**

This supports applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias. The total budget is worth USD 8 million to fund five to eight awards in fiscal year 2017.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Promoting caregiver health using self-management (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to stimulate research in promoting informal caregiver health using self-management. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Oral anticancer agents – utilisation, adherence and health care delivery (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This aims to assess and describe the current state of oral anticancer medication utilisation, delivery and adherence, identify structural, systemic, and psychosocial barriers to adherence and develop models and strategies to improve safe and effective delivery of these agents so

that clinical outcomes are optimised. Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports research projects including small-scale physiologic studies in humans or secondary analyses of data and stored biospecimens from controlled clinical intervention studies, to increase the understanding of the clinical translational potential of

metformin to delay deleterious ageing changes or to extend healthy human life span. Application budgets need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Fertility status as a marker for overall health (R01)

### **NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

This supports research that explores the premise that fertility status can be a marker for overall health. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Academic-industrial partnerships to translate and validate in vivo cancer imaging systems (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This aims to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment and disease status. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Chronic condition self-management in children and adolescents (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This encourages research that aims to improve self-management and quality of life in children and adolescents with chronic conditions. Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Reducing health disparities among minority and underserved children (R01 clinical trial optional)

### **NIH: National Institutes of Health**

This encourages research that targets the reduction of health disparities among children. Application budgets are not limited but need to reflect the actual needs of the proposed project. The

maximum project duration is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Reducing overscreening for breast, cervical and colorectal cancers among older adults (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This promotes research on intervention based in healthcare settings, designed to reduce overscreening for breast, cervical or colorectal cancers among average-risk older adults. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project duration is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)



## Basic mechanisms of brain development mediating substance use and dependence (R01)

### **NIH: National Institute on Drug Abuse**

This supports applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behaviour and in substance use and dependence. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)





## Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional)

### **NIH: National Institute of Mental Health**

This encourages applications focused on advancing understanding of mechanisms by which mental health affects HIV, and developing and testing expanded interventions to improve both mental health and HIV outcomes. Application budgets are not limited but need to reflect

the actual needs of the proposed project. The scope of the proposed project period is five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Advancing our understanding of the brain epitranscriptomics (R01)

### **NIH: National Institute of Mental Health**

This supports research into the functions of modified RNAs in the brain and in the associated modification proteins that act on RNA that play a role in basic neurobiological and behavioural processes implicated in mental and substance use disorders. Application

budgets are not limited but need to reflect the actual needs of the proposed project.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)

## Cancer tissue engineering collaborative – enabling biomimetic tissue-engineered technologies for cancer research (R01 clinical trial optional)

### **NIH: National Cancer Institute**

This supports the development and characterisation of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Budgets are limited to USD 400,000

in direct costs per year for a maximum of five years.

**Closing date: 05 Jun 19**

[Link to \\*Research Professional](#)